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2 Introduction 
2.1 Macromolecular therapy - a brief survey 
Today most of the drugs prescribed belong to a group of molecules smaller than 500 
Da (1). In most cases, these small molecules can be obtained through direct 
chemical synthesis. Due to their small sizes and their partition coefficient, they are 
usually able to freely diffuse through the plasma membrane bilayer and get to their 
site of action. In general small molecules share a common mode of action. They are 
usually blocking the active site of a target molecule, either by covalent coupling or 
just by intermolecular interaction. Due to lack of specificity this often causes 
unwanted side effects and in consequence toxicity occurs. In contrast 
macromolecules, e.g. nucleic acids or proteins, in most cases exhibit high specificity 
for their target molecule. This is rooted in their complex structure. The complexity 
does not only reduce the risk of unwanted interactions, but primarily it opens the door 
for a large set of functionalities that cannot be mimicked by small molecules (2). 
Macromolecules, of rather high molecular weight and often multiple charged, are in 
most cases not able to overcome the cytoplasmic membrane. Because of this reason 
the application of macromolecular drugs is mainly limited to therapeutics, whose site 
of action is located extracellular or on the cell surface (3-7). The first clinical used 
macromolecular therapeutic was insulin which was extracted from bovine pancreas in 
1922 by Lilly (8). Problems, like availability of pancreases for purification, high costs 
and immunological reactions of some patients hindered a widespread use. Although 
these problems could not be solved at this time, this successful application slowly 
shifted the focus of drug development from small molecules to macromolecular 
compounds. In the following 40 years many endogenous proteins with therapeutic 
potential have been identified (9, 10). But it took the development of recombinant 
DNA technique and modern biotechnology which enabled easy and cheap production 
of large amounts of recombinant proteins, leading to the explosion of the 
biopharmaceutical market. Aside low costs and easy scale up, recombinant produced 
proteins have got several therapeutic advantages compared to other protein sources. 
Due to the transcription and translation of the exact human gene, they lower the risk 
of immunogenic responses and often have got higher specific activity. Up to date 
nearly 100 recombinant proteins are approved by the FDA for clinical use (2). Plenty 
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of diseases, e.g. cystic fibrosis or Duchenne muscle dystrophy are the result of a 
mutation in a protein encoding gene. The growing knowledge in genetics and 
biotechnology also opened the door for gene therapy, a concept of treating such 
diseases on their molecular origin. The basic idea of gene therapy, replacing the 
deficient gene with a functional copy, arose during the 1960s and 1970s, when the 
first evidences for uptake of exogenous DNA in mammalian cells have been found 
(11, 12). From this point of time things went on quite fast. The first approved human 
gene therapy trial was performed by Rosenberg and colleagues in 1989. They used 
retroviruses to introduce a gene encoding for resistance to neomycin into human 
tumor-infiltrating lymphocytes prior to reinfusion into patients with advanced 
melanoma (13). Despite some severe  backlashes, up to date more than 1700 clinical 
studies on human gene therapy are either in process or even have been finished 
(Gene Therapy Clinical Trials Database). Besides DNA, diverse other nucleic acids, 
like antisense RNAs (14), messenger RNAs (15), 2'-O-alkyl RNAs (16), aptamers 
(17), phosphorothioate DNAs (PS-DNA) (18), inosine-cytosine RNAs (polyIC) (19), 
decoy oligonucleotides (20), and LNAs (21) are in the clinical trial phase or are 
already used in macromolecular therapy. Among these nucleic acid based 
techniques, siRNA mediated RNA interference is rising particular hope, as it can be 
used for both up- (22) and down- regulation of a gene. Since Tuschel and coworkers 
(2001) showed that synthetic siRNAs can down regulate gene expression in 
mammalian cells (23) and Andrew Fire together with Craig Mello won the Nobel Prize 
(2006) for their work on RNA interference, more than 30 clinical trials on siRNA 
mediated RNA interference have been started (24). All nucleic acid based therapies 
inherence the risk of potential interaction of the delivered macromolecular drug with 
the DNA of the target cell. In worst case, this can lead to severe damage of the 
treated organism (25). 
Intracellular delivery of active proteins supplementing dysfunctional cellular proteins 
is an encouraging alternative to gene therapy (26, 27). It is expected to be a safe 
approach, lacking the potential malignant transformation of viral gene therapy (28). 
Protein transduction presents the most straight forward plan of attack for healing 
plenty of diseases caused by mutated or wrong folded proteins (29). The first protein 
observed, having the ability to translocate through the intact phospholipid bilayer, 
was the HIV-1 TAT protein (30, 31). In the meantime, it has been discovered that 
natural homeoproteins such as the Antennapedia homeobox can cross cell 
Introduction  13 
membranes and internalize into cells as part of their physiological function (32) and 
numerous homeoprotein-derived natural and artificial transduction peptides have 
been identified. (33-36) Thus, the intracellular delivery of active proteins, named 
‘protein transduction’, now is considered as an interesting option and alternative to 
gene therapy, substituting for dysfunctional cellular proteins (27, 29, 37). After this 
observation in 1988, it took almost another 20 years until the first clinical trials using 
this new technique started. Clinical trials include treatment of various diseases, e.g. 
dermal scar therapy, psoriasis, pulmonary fibrosis, hyperhidrosis. Altogether up to 
date over 20 Phase 1 and Phase 2 clinical trials were performed and more than 2000 
patients have been treated with drugs, delivering peptides or proteins into cells (38). 
A Phase 2a clinical trial in the treatment of Lateral Canthal Lines showed significant 
efficacy versus a placebo. The therapeutic is based on a Botulinum Toxin Type A 
protein, which is delivered by a protein transduction domain (PTD). Moreover the 
drug appears to be well tolerated. Although protein transduction technology is still in 
its infancy, it raises hope in the development of new macromolecular drugs for the 
treatment of numerous diseases caused by dysfunctional cellular proteins. Although 
tremendous progress was made in the last decade, all of the macromolecular therapy 
techniques, except the extracellular operative ones, share a common difficulty – 
without effective delivery into the cell their therapeutic use is very limited. 
 
2.2 Barriers in macromolecular therapy 
On the long rocky road to the site of action, the macromolecular drug has to 
overcome many hurdles. So many different critical steps have to be addressed. First 
problem is to decide what´s the right administration form of a certain macromolecular 
drug. Oral application of a macromolecular drug in most cases does not make sense, 
as the therapeutic would be rapidly degraded inside the intestinal tract. One 
possibility to get an adequate quantity of the drug to the target is local injection, 
followed by passive diffusion of the macromolecular medicate. Presumably the 
treatment of age related macula degeneration with siRNA represents the most 
spectacular example of this administration form (39). Major disadvantage of this 
method is that far not all tissues and cells can be reached. Most inner organs as well 
as tumor tissue have got strong blood circulation and therefore are good accessible 
through direct intravenous injection. Once inside the blood flow the macromolecular 
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drug is confronted with a hostile environment. The macromolecular drug is 
threatened with degradation by proteases, nucleases, phagocytotic cells of the 
immune system and many more. One possibility to reduce interaction with these 
components is PEGylation of the macromolecular therapeutic. Polyethylene glycol  
(PEG) is a uncharged, hydrophilic polymer which was shown to reduce 
immunogenicity and enhances circulation live of proteins (40). Also unspecific 
interaction of DNA polyplexes with blood components could be minimized through 
this way (41).  Next hindrances that have to be mastered are clearance by liver and 
kidney which presents a particular problem in delivery of macromolecules (42). In this 
case again PEGylation can be used to increase size, as the kidney allows clearance 
mainly of particles below 8 nm. Next step is the extravasation of the therapeutic to 
the target cell through the extra cellular matrix. Especially for electrostatic DNA or 
siRNA polyplex formulations this represents a critical step that may be limiting 
effective drug delivery (43). Macromolecules, whose site of action is on the cell 
surface, e.g. surface receptor ligands (44) or antibodies binding to extracellular target 
(45) have already reached their final destination on this stage. For macromolecular 
drugs acting in the cytosol the major delivery problems are just starting at this point. 
Now they have to overcome the biological barrier of the cytoplasmic membrane, a 
phospholipid bilayer structure whose primary natural function is to prevent the 
uncontrolled cell entrance of such big and charged molecules (molecular weight cut-
off around 600 Da) (46).  
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Scheme 2.1: Illustration of uptake pathways for mac romolecular drugs and further processing 
of the internalized vesicles. Except caveolae media ted endocytosis, all other cellular entries 
lead at least partly to fusion of the vesicles with  lysosomes and therefore to acidic degradation 
of the cargo.  
Endocytosis is a natural occurring process that allows the directed uptake of 
molecules, for example Fe3+. Iron is internalized after binding of iron loaded 
transferrin to the transferrin receptor (47). Macromolecular drugs can use this cellular 
feature to penetrate into the target cell, when ligands like Transferrin (48), Folate 
(49), EGF (50), RGD (51), B6 (51) or GE11 (52) are associated to their surface. 
Literature describes, as illustrated in Scheme 2.1, at least five different ways of 
endocytosis: phagocytosis, clathrin-mediated endocytosis, macropinocytosis, 
caveolae-mediated endocytosis, and clathrin-caveolae-independent endocytosis 
(53). Targeted uptake occurs mainly via clathrin mediated endocytosis (54). Also 
unspecific binding of a macromolecular drugs to the cell, e.g. via electrostatic 
interaction can lead to internalization. In this case all pathways can be involved (55, 
56). Except caveolae mediated endocytosis, all other cellular entries lead at least 
partly to fusion of the vesicles with lysosomes and therefore to acidic degradation of 
the internalized macromolecules (57). To prevent this, the therapeutic has to escape 
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from endo-lysosomal degradation. As most macromolecular drugs are not able to 
disrupt the endosome membrane themself, a second molecule providing this feature 
is needed. In case of DNA polyplexes this often is the cationic polymer 
polyethylenimine (PEI). PEI polymers possess protonable primary, secondary or 
tertiary amines, with a pKa between five and seven which can buffer acidification of 
the late endosomes by taking up protons. This buffering goes along with concurrent 
influx of chloride to maintain charge neutrality and results in an increased ionic 
strength inside the endosome. To balance this, water is accumulating passively 
inside the endosome. Therefore the pressure inside the endosome increases more 
and more until the membrane bursts and the content of the endosome is released 
into the cytosol (58). Lipid based carriers present another possibility to destabilize the 
endosome membrane and promote release of the entrapped therapeutic (59-61). A 
third well known strategy to promote endosomal release is the use of lytic, membrane 
disrupting peptides, for example melittin. Melittin the main active compound in bee 
venom inserts into the phospholipid bilayer where it forms pores and leads to 
membrane disruption (62). As the lytic properties are not pH specific, melittin is also 
interacting with other membranes and therefore exhibits quite high toxicity. In 
contrast to melittin the lytic influenza peptide develops its lytic activity through a 
change in conformation which occurs after acidification. Because of this property it is 
a great reagent for enhancing endosomal release (63). Although some chemicals, 
e.g. Chloroquine, can prevent endosomal acidification and therefore enhance 
endosomal escape, their inherent toxicity excludes therapeutic applications (64-66). 
Although after endosomal release most drugs have reached their destination, they 
have to get rid of all modifications to develop their natural behavior. Some 
therapeutics, like DNA or transcription factors, need to be further translocated 
subcellularly to the nucleus, their site of action. Subcellular nuclear transport presents 
a major bottleneck in DNA delivery (67). Proteins exposing their nuclear localization 
signal are translocated into the nucleus by binding of the cytosolic, heterodimer 
carrier protein importin. Importin binding is resulting in a GTP driven active transport 
through the nuclear pore complex (68).    
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2.3 Nucleic acid versus protein delivery 
 
 
Scheme 2.2: Illustration of differences and similar ities in further processing, after cellular 
uptake of nucleic acids and proteins (Scheme partly  adapted from David Schaffert (69)). 
Intracellular delivery of active proteins supplementing dysfunctional cellular proteins 
is an encouraging alternative to gene therapy (26, 27). First difference of nucleic acid 
and protein delivery is the different stability of the naked molecules in plasma. For 
example Houk et al. showed that naked linear DNA has got an half-life of only 11 
minutes in isolated rat plasma (70), whereas proteins have got an half-life of up to a 
few hours (71). Protein transduction presents the most straight forward plan of attack 
for healing plenty of diseases caused by mutated or wrong folded proteins (29). A 
DNA molecule delivered into the cell is acting as a kind of prodrug, because it has to 
be further processed by the cell to develop its therapeutic effect. First the DNA has to 
be transcribed into mRNA and the mRNA has to be translated into the protein to get 
the active compound (Scheme 2.2). Up-regulation of a gene encoding for a certain 
protein via RNAi technique is even more complicate. In this case the siRNA must 
knockdown the translation of mRNA encoding for a suppressor protein of the 
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accordant gene. This leads to enhanced transcription and therefore translation of the 
desired gene (22). Delivery of mRNA is again a step closer. In this case the 
internalized mRNA is active in the cytosol and just has to get transcribed to result in 
the corresponding active protein (72). Aside that protein delivery has got several 
other advantages compared to nucleic acid delivery. It is expected to be a safe 
approach, lacking the potential malignant transformation of viral gene therapy (28). In 
addition protein transduction technology offers the possibility to transport proteins into 
the cytosol, containing artificial or D-amino acids, which are considered to be less 
immunogenic (62) and more stable towards intracellular degradation. Harris and 
coworkers have shown that shortening of the amino acid sequence and replacement 
of L-amino acids through  their D-AA analog raises half-life time of Somatostatin from 
a few minutes up to 1.5 hours (73).  A well-known bottleneck in nucleic acid delivery, 
the transport of the DNA into the nucleus (74), which is indispensable for target gene 
expression, is easily bypassed. Most proteins have got their site of action inside the 
cytosol. Nevertheless some therapeutic proteins like transcription factors also have to 
be subcellularly transported into the nucleus to get active. But in contrast to DNA this 
is much easier, just because of the smaller size of proteins. The nuclear pore 
complex has got a diameter of around 8 nm which allows passive diffusion of 
molecules up to 40 kDa into the nucleus. Bigger proteins are only transported into the 
nucleus through an energy dependent process, when they are bearing an exposed 
nuclear targeting sequence (68). One big drawback of protein delivery in comparison 
to gene therapy is that especially for enzymes their tertiary conformation is essential 
for the activity. This tertiary structure may be disturbed by coupling carrier molecules 
for example CPPs. Typically nucleic acids like plasmid DNA is forming a stable 
polyplex with most cationic carrier molecules, held together by electrostatic 
interactions. In contrast complexation of proteins, because of the lower density of 
negative charges on the surface, affords in most cases covalent coupling of the 
carrier molecule to the protein cargo. Kataoka and coworkers presented another 
smart technique to overcome this problem. They substituted the positive charges of 
lysine residues in proteins through negative ones by reaction with citraconic 
anhydride, thus charge density is high enough for non-covalent complexation (75). 
Another major difference may be for some cases an advantage and for other ones a 
disadvantage. In contrast to protein transduction, cells transduced with DNA are 
expressing the encoded protein, dependent on the used promoter, quite a long time 
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(76). Protein delivery is a short termed treatment, because the internalized proteins 
are degraded by proteases after a while. To sum up nucleic acid as well as protein 
delivery has its special features and offers specific advantages over the other one. 
 
2.4 Strategies for transporting proteins into the c ytosol of 
living cells 
Proteins have to overcome the biological barrier of the cytoplasmic membrane to get 
into the cytosol. As already mentioned this phospholipid bilayer structure was 
designed from nature for preventing the uncontrolled entering and exiting of such big, 
charged molecules. For pure in-vitro studies, it is possible to use physical methods, 
like microinjection or electroporation, to promote an uptake of the desired peptide or 
protein (77, 78). With the help of a microinjector the cytoplasmic membrane of 
individual cells is perforated with a thin glass capillary and the protein is directly 
injected into the cytosol. Because of the big effort only a few cells can be addressed 
with this technique and in addition quite a great amount of the cells do not survive 
this treatment. Electroporation in contrast to microinjection is a technique which is 
also applicable for in vivo application (79). An externally applied electrical field is 
temporarily changing the conformation of membrane properties, resulting in an 
increase in membrane permeability. During this short time interval proteins can 
overcome the phospholipid bilayer. In opposite to these rather brute physical 
methods, for moderate biological techniques having the potential for broad 
therapeutic application, in most cases a carrier molecule is needed. On the rocky 
road into the cytosol, the transduction carrier has to prevent the cargo from 
extracellular degradation and transport it piggyback over the biological barrier of the 
cytoplasmic membrane. Once inside the cell the carrier-cargo complex has to escape 
from endo-lysosomal degradation. Afterwards the carrier should release its cargo in 
the cytosol to warrant activity of the protein. A perfect carrier system has to address 
all this critical steps and furthermore exhibit low cytotoxicity. In the last decades many 
efforts have been made to create such a perfect carrier system. In 2010 Voelkel et al. 
presented a technology for protein delivery, where they transported GFP into the 
cytosol of living cells using murine retroviral particles as carrier system (80). Quite a 
similar system were they used lentivirus derived virus like particles (VLPs) was 
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developed by Frederico and coworkers (81). Major drawback of these virus based 
systems is the presence of reverse transcriptase and integrase in the particles which 
causes the potential risk of conversion of RNAs into DNA and integration of DNA into 
the chromosome of the transduced cell (82). Dai and colleagues used single walled 
carbon nanotubes (SWNT) for the delivery of streptavidin and cytochrome c in a 
number of different cell lines (83-85). Aside carbon nanotubes, also another inorganic 
carriers, e.g. mesoporous silica nanoparticles (MSN) and gold nanoparticles were 
successfully used to deliver proteins into cells (86-88). Major drawback of this 
carriers based on inorganic compounds is that the protein is attached to their surface, 
where it is not protected against proteases and in many cases the shuttles exhibit low 
endosomal escape. Most commercial available carriers for protein delivery are based 
on cationic lipids (89-91). Liposomes are supposed to enter cells via two different 
mechanisms, endocytosis or fusion of the liposome with the cell membrane (92). 
Later uptake mechanism offers the advantage that the cargo is not internalized in 
endosomes but is rather directly discharged into the cytosol. Main disadvantage is 
the low stability of most cationic lipid based vectors under serum containing 
conditions that hampers effective protein uptake (93). The first protein observed that 
was naturally able to translocate through the intact phospholipid bilayer was the HIV-
1 TAT protein (30, 31). In the meantime, it has been discovered that natural 
homeoproteins such as the Antennapedia homeobox can cross cell membranes and 
internalize into cells as part of their physiological function (32) and numerous 
homeoprotein-derived natural and artificial transduction peptides have been 
identified. (33-36). Thus, the intracellular delivery of active proteins, named ‘protein 
transduction’, now is considered as an interesting option and alternative to gene 
therapy, substituting for dysfunctional cellular proteins (27, 29, 37). The most 
common method used for protein delivery is the use of short positively charged 
peptides, so called protein transduction domains (PTDs) (27, 94-96). These PTDs 
can be grouped in two major classes, natural ones like Penetratin (96, 97) or HIV-
TAT (27) and artificial ones e.g. oligoarginines (98). Protein transduction domains 
(PTDs) or also called cell penetrating peptides (CPPs) in general are tagged to the 
cargo protein by genetic engineering. Especially in cases where the active center of 
an enzyme is located near the carboxy- or amino-terminus this tags can disturb 
functionality. The internalization pathway of these fusion proteins is discussed 
controversial. Some studies suggest macropinocytosis (97, 99) others predicate it is 
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a mixture between different mechanisms (100). At least uptake means may be 
dependent on the used CPP, cell line, concentration and cargo (101, 102). The 
efficiency of the following step, the retrograde transport out of the endosome is very 
low for most PTDs (103, 104). Altogether the efficiency of this technique seems to be 
dependent on cell line and cargo size (98, 101). Okuyama et al. engineered a 
synthetic carrier system that is mimicking an alpha helix found in some PTDs. 
Covalent coupling of this small molecule based carriers (SMoCs) to the DNA 
replication licensing repressor protein geminin showed an antiproliferative effect on 
human cancer cells (105).  Aside PTD mediated protein delivery the use of cationic 
polymers, e.g. polyethylenimine is a widely used strategy for protein transduction (75, 
106-109). Cationic polymers like polyethylenimine often are very effective carriers, 
but are lacking of precise structure and often show high toxicity dependent on the 
molecular weight of the used polymer (110). Up to date protein delivery still lacks of 
an all-purpose carrier system. Each of the presented technologies has got its 
limitations. Some technologies show cell type dependence (98) or others are 
bordered to certain cargo proteins (111). 
 
2.5 Biological cleaveable crosslinkers 
Today plenty of different protein crosslinkers are on the market. They are used for 
many different applications, e.g. for analysis of protein structure and subunits, 
formation of protein- protein conjugations, immobilization of proteins on solid phase, 
PEGylation, formation of crosslinks between nucleic acids and proteins, analysis of 
protein interactions, preparation of immunogens or for the construction of 
immunotoxins. For some applications it is of favor that the bond between the 
crosslinked molecules is reversible and can be cleaved under certain conditions. Also 
for this acquirement linkers are available. Linkers containing internal esters, e.g. the 
ethylene glycolbis(succinimidylsuccinate) (EGS) can be cleaved by incubation with 
hydroxylamine (112, 113). Introduction of diol containing groups that can be cleaved 
by periodate is also a very common technique in crosslinker development (114, 115). 
Base labile crosslinkers based on sulfone groups present another group of 
commercial linkers (116-118). Although all these presented linkers are cleavable 
under conditions which are compatible for most proteins, they do not allow a 
cleavage under such mild chemical conditions compatible with a living biological 
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system. Furthermore for intracellular macromolecular drug delivery it is of advantage 
to have a chemical dynamic linker triggered by tiny changes in chemical 
microenvironment. During the delivery process the chemical microenvironment 
changes with the further transport of the macromolecular drug to another cellular 
compartment. The linker should respond to this tiny chemical changes in the required 
manner. For example the linker should be stable in the extracellular matrix, before 
cellular uptake and after internalization the bond between carrier and cargo should 
be cleaved. Nearly all commercial available crosslinkers providing this feature are 
based on bioreducible disulfide bonds (119-122). The most famous under this type of 
linkers is the heterobifunctional crosslinker (SPDP), which was developed by Carlson 
et al. in 1978 (119). One end is built up from an amine reactive succinimidylester that 
can be reacted with the amine group of lysine containing proteins, resulting in a 
stabile amide bond. The other functional group is a 2-pyridyldithio group which allows 
reaction with sulfhydryl containing molecules (e.g. cysteine residues of proteins or 
peptides), forming a disulfide bond. This disulfide bond is stable in a non-reducing 
environment, for example in the extracellular matrix. Under mild reducing conditions 
in contrast, (e.g. caused by glutathione levels in the cytosol), it is cleaved (123, 124). 
An additional feature of SPDP is that the cleavage of the 2-pyridyldithio group causes 
a change in the spectral properties and therefore it is quite easy to determine the 
amount of linker coupled to the desired molecule. For this reasons SPDP became the 
most used linker in macromolecular drug delivery (123, 125-127). Photo-cleavable 
linkers present another strategy that allows controlled cleavage of the bond between 
two crosslinked molecules (128-130). Ottl and coworkers developed a 
hetrobifunctional linker, which contains a photoreactive o-nitrobenzyl group (129). 
Upon light stimulus the linker is cleaved. Photocleavable linkers are applicable mainly 
for in vitro uses, because deeper tissues can hardly be addressed. Knorr et al. 
presented a homobifunctional acetone ketal cross-linker in 2008 that capitalizes from 
the differences in pH in different cellular compartments or tissues (131). The inherent 
acetal group is cleaved under mild acidic conditions, which are typical for tumor 
tissue (132) or early endosomes (133), whereas the linker is quite stable under 
physiological pH of 7.4. All cleavable linkers presented have in common that they are 
not cleaved off completely. After cleavage a small relict of the linker remains bound to 
the molecule of interest. For some applications like protein delivery this might be a 
drawback, e.g. the active site of an enzyme could be sterically blocked by this 
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fragment. Blätter et al. created a heterobifunctional, acid labile linker in 1984 that is 
based on maleic anhydride. This linker is cleaved off traceless from the molecule of 
interest upon acidification (134).  Major drawback of this linker is that it requires quite 
low pH values to be cleaved. A linker especially developed for protein delivery was 
presented by Dowdy and colleagues in 2010 (27). It is based on nitrilotriacetic acid 
(NTA) coordinated copper that is strongly binding to hexahistidine-tagged 
macromolecules like peptides and proteins. This affinity is lost after a pH drop to 5 
which can be found as already mentioned in late endosomes. Major drawback of this 
linker is that exclusively the histidine bearing end of the protein can be modified and 
therefore no real encapsulation is possible. Up to date still no perfect linker system 
for protein delivery is available. 
 
2.6 Aims of the thesis 
2.6.1 Establishment of a cellular test system for p rotein delivery  
Aim of this thesis was to establish a test system for protein delivery. The test systems 
should enable easy and fast qualitative proof of successful protein internalization. 
The protein should be of average size and exhibit a typical isoelectric point (pI). 
Furthermore it should be possible to evaluate the percentage of transfected cells, as 
well as the amount of protein that was taken up by the cells. As a “golden standard”, 
one corresponding model protein should be established bearing a very common PTD 
like HIV-TAT peptide. This CPP should be fused to the model protein by genetic 
engineering. This standard protein transduction technology should serve as a 
reference test method, to evaluate and compare the efficiency of different developed 
carrier systems. One of the major bottle necks for protein delivery is, as already 
mentioned endosomal release. The test model ought to demonstrate easy, if the 
cargo is released out from the endosome and is behaving naturally inside the cytosol, 
e.g. through successful subcellular transport. Furthermore the test system should be 
able to evidence that biologic activity of a transported enzyme is maintained. A model 
of such a test system is illustrated in Scheme 2.3. 
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Scheme 2.3: Illustration documenting the concept of  the planed protein delivery test system. 
386 is a precise oligo(ethane amino)amide carrier. SPDP is a protein crosslinker. 
 
2.6.2 Protein delivery with defined polycations 
The most widespread technique for delivery of proteins is the use of CPP as carrier 
system (27, 94-96). As already mentioned such delivery is of low efficiency especially 
since endosomal escape is very low (103, 104). At least efficiency seems to be 
limited to certain cell lines and cargos. For that reason an efficient delivery system 
that is applicable for a huge amount of proteins on many different cell lines should be 
developed. In contrast to PTDs an artificial polycation should be used as carrier 
system. Up to date for protein transduction mostly PEI has been used as a 
polycationic carrier (75, 106-109). PEI is a highly efficient carrier but it is a polymer 
that lacks of defined, precise chemical structure and exhibits quite high toxicity. For 
this thesis a structure defined, precise oligo(ethane amino)amide carrier should be 
used. These carriers were developed recently in our lab for the delivery of siRNA and 
DNA (59). The oligo(ethane amino)amide carriers are based on natural and synthetic 
amino acids and were synthesized with solid phase supported chemistry. Because of 
their low molecular weight they exhibit low toxicity. Nevertheless they show high 
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transduction efficiency in case of nucleic acid delivery. This high transduction 
efficiency, aside of the good complexation properties and the ability to form stable 
polyplexes, might be a result of their endosome destabilizing properties. Because of 
these promising results in nucleic acid delivery, the carriers should be tested for their 
ability to transport proteins into the cytosol of living cells. 
 
2.6.3 Development of a new traceless cleavable link er for protein 
delivery 
Aside the establishment of a test system for successful protein delivery and the 
development of a new protein transduction technology, the synthesis of a linker 
designed for intracellular protein delivery was the major aim of this thesis. The new 
linker should fulfill following requirements for protein delivery. The bond between 
carrier and cargo should be stable under physiological conditions that means 
especially under serum containing conditions at pH 7.4. After uptake the linker should 
be cleaved off traceless form the cargo to release an unmodified natural protein. This 
desired feature is demonstrated in Scheme 2.4. The linker cleavage should be 
triggered by the pH drop in the endosome. At a pH of around 5 the linker should 
release the carrier from the cargo completely. Furthermore the linker system should 
allow the complete encapsulation of the protein with the carrier molecule. In recent 
years click chemistry reactions, especially the copper catalyzed 1,3-dipolar 
cycloaddition (CuAAC) and the Staudinger ligation, became useful tools for 
conjugating biomolecules (49, 135-137). Both reactions have great advantages 
compared to other linking strategies, like high efficiency and bioorthogonality. The 
new linker should enable the use of these click chemistry reactions for covalent 
modification of the cargo protein with the carrier.    
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Scheme 2.4: Illustration of the linker concept. Scheme (138) is showing the linker coupling a carrier 
over CuAAC to nlsEGFP. Furthermore all major desired properties of the new linker are displayed: 
heterobifunctionality, bioorthogonality, using click chemistry, complete encapsulation, acid lability, 
traceless cleavage.
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3 Materials 
3.1 Chemicals 
All used chemicals, unless noted otherwise, were purchased from Sigma-Aldrich and 
used without further purification. 
 
3.2 Reagents 
3.2.1 Dyes 
Dylight 488 a phosphine containing dye for copper free click chemistry coupling over 
Staudinger ligation was purchased from Thermo Fisher Scientific (Schwerte, 
Germany). Tetramethylrhodamine-5-maleimide was bought from Sigma-Aldrich 
(Munich, Germany). 
 
3.2.2 Peptides 
Cystein modified melittin (Mel) with following sequence CIGA VLKV LTTG LPAL ISWI 
KRKR QQ, in all D conformation, was ordered from IRIS biotech (Marktredwitz, 
Germany). The N-terminal cysteine was introduced as an amine and the C-terminal 
amino acid as carboxylic acid. 
 
3.2.3 Linkers 
The copper free click chemistry linkers DBCO-PEG4-maleimide and DBCO-NHS 
were purchased from Jena Bioscience (Jena, Germany). The heterobifunctional 
SMCC crosslinker was ordered from Pierce Biotechnology (Bonn, Germany). 
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3.3 Solvents 
DCM, MeOH, THF were purchased from Merck (Darmstadt, Germany). CHCl3, n-
hexane, n-heptane, DMSO, ACN, Et2O were obtained from Sigma Aldrich (Munich, 
Germany). All solvents were purified by distillation and dried before use. Water was 
used after purification and deionization. Deuterated solvents were bought from Sigma 
Aldrich. 
 
3.4 Buffers 
PBS buffer was prepared with following mixture: NaCl 137 mM, KCl 2.7 mM, 
Na2HPO4 x 2 H2O 2mM, pH 7.4. If another pH value is stated it was adjusted with 
aqueous 1M HCl or NaOH solution. 
 
3.5 Solutions 
Click solution A was freshly prepared by dissolving CuBr (1 mg, 7 µmol) in 
DMSO/tert-ButOH (70 µl, 3/1, v/v). Click solution B was prepared by dissolving 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 2.7 mg, 5µmol)) in 
DMSO/tert-ButOH (3/1, v/v) (100 µl). Click solution C was freshly prepared by mixing 
click solution A and click solution B (1/2, v/v). 
   
3.6 Cell culture material 
All cell culture consumables (flasks, dishes, well plates) were purchased from NUNC 
(Langenselbold, Germany) or TPP (Trasadingen, Switzerland). Growth media, as 
well as FCS, Glutamine, Penicillin/Streptomycin were ordered from Invitrogen 
(Karlsruhe, Germany). 
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3.7 Cell lines 
All cell lines were purchased from the american type culture collection (ATCC, Wesel, 
Germany). The used cell lines are listed in Table 3.1. 
 
Table 3.1: Used cell lines 
Name Description ATCC number 
HeLa human cervix adenocarcinoma cell line CCL-2 
Neuro2A murine neuroblastoma cell line CCL-131 
NIH/3T3 murine fibroblast cell line CRL-1658 
KB human nasopharyngeal epidermoid carcinoma cell 
line 
CCL-17 
 
3.8 Bacteria strains 
Chemical competent E.coli protein expression strain BL21(DE3)plysS was purchased 
from Novagen (Merck4biosciences, Darmstadt , Germany). 
E. coli strain DH5α was bought from Invitrogen (Karlsruhe, Germany) and was used 
for plasmid amplification. 
 
3.9 Nucleic acids 
The plasmid pRHGPCNA containing a gene encoding for a nuclear localization 
sequence (derived from SV 40 large T antigen) bearing nlsEGFP fusion protein was 
kindly provided by M. Cristina Cardoso (TU Darmstadt, Germany). For heterolog 
protein expression the plasmid pET 23a (+) vector from Novagen 
(Merck4biosciences, Darmstadt, Germany) was used. 
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 Primers with following base sequences were used: 
a) For nlsEGFP amplification following oligonucleotides were purchased from 
Eurofins MWG (Ebersberg, Germany): 
forward: 5´-GTTGATGAATTCCCGAAGAAGAAGCGCAAAGTA-3`;  
reverse: 5`-TCAACTAAGCTTCTTGTAAAGCTCGTCCATGCC-3`. 
 
b) For introducing the HIV-TAT PTD sequence following oligonucleotides were 
ordered from Eurofins MWG (Ebersberg, Germany) 
Sense: 
5`AGCTTGGTTATGGGCGCAAAAAACGCCGTCAGCGCCGTCGGGGCC3` 
Antisense: 
5`TCGAGGCCCCGACGGCGCTGACGGCGTTTTTTGCGCCCATAACCA 3`  
4 Methods 
4.1 General chemical procedures 
4.1.1 1HNMR and 13CNMR 
The 1H-NMR and 13CNMR spectra were recorded at room temperature using a 
JNMR-GX (400 MHz, Joel) or a JNMR-GX 500 (500 MHz) with a coupling constant of 
0.3 Hz. All spectra were recorded without TMS as internal standard and thus spectra 
were calibrated to the residual proton signal of the deuterated solvent. For the 
measurements 10-100 mg sample were used. Spectra were analyzed using the NMR 
software MestreNova (MestreLab research) or NUTS (Acron NMR). 
 
4.1.2 Mass spectroscopy 
Mass spectra were recorded on a Thermo Finnigan MAT 95 or on a Jeol MStation.  
 
4.1.3 CD spectroscopy 
nlsEGFP was diluted in phosphate buffer (50mM, pH 7.5, 1mg/ml). Spectra were 
recorded on a Jasco J810 CD and ORD spectrometer. 386-DBCO-AzMMMan-
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nlsEGFP was dialyzed against citric acid-phosphate buffer (0.1 M, pH 5) at 37°C 
overnight to cleave off the transduction oligomer 386. This was followed by another 
dialysis step against phosphate buffer (50mM, pH 7.5, 1 mg/ml) for 12 hours. The 
dialysis was performed using a 14000 MWCO dialysis membrane from Carl Roth 
(Karlsruhe, Germany). The protein was concentrated to 1 mg per ml with Amicon 
Ultra centrifugal filter units (MWCO=10,000). 
 
4.1.4 UV-Vis spectroscopy 
Protein, linker concentrations, etc. were determined by measuring UV-Vis 
absorbance at different wavelengths. For these measurements a Genesys 10 S UV-
Vis spectrophotometer (Thermo Scientific, Bonn, Germany) was used. 
 
4.1.5 Fluorescence spectroscopy 
For fluorescence spectroscopy a Varian Cary Eclipse (Darmstadt, Germany) 
fluorescence spectrophotometer was used. Proteins were diluted in PBS buffer (pH 
7.3). 
 
4.1.6 Chromatography 
4.1.6.1 HPLC 
HPLC runs were performed either on a GE Healthcare ÄKTA Basic system or on a 
Bio-Rad (München, Germany) BioLogic FPLC station. The Äkta system is built up 
from a P-900 dual-pump, a UV-900 three channel UV-detector and F-950 fraction 
collector. The system was controlled by the appropriate UNICORN software (version 
4.11). The BioLogic Workstation is containing two pumps, 6 valves, a conductivity 
meter and an external UV-detector. The system is operated by the BioLogic version 
1.3 software. A fraction collector model 2180 also from Bio-Rad was used.   
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4.1.6.2 Dry column vacuum chromatography (DCVC) 
Dry column vacuum chromatography was done as described by Pederson and 
colleagues (139).   
 
4.1.6.3 Flash Column Chromatography (FCC) 
Flash chromatography was performed as described by Still and coworkers (140). As 
stationary phase silica gel with a mean diameter between 0.035 and 0.073 mm was 
used. Column height and diameter were varied according to sample size and the 
required resolution. 
 
4.1.6.4 Thin layer chromatography (TLC) 
Silica gel coated aluminium plates were used for thin layer chromatography. 
Detection method was UV-detection at 254 nm. 
 
4.1.7 Dynamic light scattering (DLS) 
Particle size and zeta potential of the transduction shuttles was measured by 
dynamic laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). Modified proteins were measured in Hepes buffer (20mM, pH 
7.4) at a concentration of 5 mg/ml. 
 
4.2 Synthesis 
4.2.1 Synthesis of watersoluble hemicyanine alkyne dye 
The watersoluble hemicyanine dye (E)-2-(4-(bis(2-hydroxyethyl)amino)styryl)-3-
(prop-2-yn-1-yl)benzo[d]thiazol-3-ium bromide was synthesized in a very 
straightforward two step reaction from methylbenzothiazole as precursor. First step is 
a nucleophilic substitution followed by a condensation of the product with 4-N,N-
bishydroxyethyl aminobenzaldehyde. 
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Scheme 4.1: Synthesis strategy of watersoluble hemi cyanine alkyne dye. (E)-2-(4-(bis(2-
hydroxyethyl)amino)styryl)-3-(prop-2-yn-1-yl)benzo[ d]thiazol-3-ium bromide 
 
4.2.1.1 Synthesis of 2-methyl-3-prop-2-ynyl-benzoth iazol-3-ium bromide 
N
S
Br
 
This compound was prepared analogously as described elsewhere (141). Briefly: 
Methylbenzothiazole (12.0 g, 0.1 mol) was given to a solution of propargyl bromide 
(5.0 g, 34 mmol) in acetonitrile (20 mL) under vigorously stirring. Subsequently the 
reaction mixture was refluxed for 24 h. Afterwards the reaction mixture was allowed 
to cool to room temperature, and the precipitate was collected. This gave the desired 
product as a grey solid (5.8 g, 21% yield); 1H NMR(500 MHz, DMSO D6) d 8.5 (d, J 
= 8.1 Hz, 1H), 8.38 (d, J = 8.5 Hz, 1H), 7.95 (t, J = 8 Hz, 1H), 7.83 (t, J = 7.8 Hz, 1H), 
5.78 (d, J = 2.5 Hz, 2H), 3.85 (t, J = 2.5 Hz, 1H), 3.27 (s, 3H). 
 
4.2.1.2 Synthesis of 2-[2-(4-dihydroxyethylamino-ph enyl)-vinyl]-3-prop-2-ynyl-
benzothiazol-3-ium bromide 
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4-N,N-bishydroxyethyl aminobenzaldehyde (0.5 g, 2.39 mmol) and 2-methyl-3-prop-
2-ynyl-benzothiazol-3-ium bromide (641 mg, 2.39 mmol) were diluted in ethanol (20 
ml) and refluxed for 2 h. Afterwards the solvent was removed in a rotary evaporator. 
The residue was purified by DCVC (dry column vacuum chromatography). First the 
column was washed with ethylacetate/methanol (9:1, v/v) followed by a washing step 
with acetone/methanol (9/1, v/v) and elution using acetone/water (1:1, v/v). Most of 
the acetone was removed by evaporation and the residue was lyophilized. This gave 
a dark purple fluffy solid (0.86 g, 78 % yield). MS (FAB+, 8 kV) calcd for 
C22H23N2O2S [M]+ 379.50, found 379.5. 1H NMR (500 MHz, [d6]DMSO)  8.30 (d, J 
= 7.82 Hz, 1H), 8.12 (m, 2H), 7.90 (d, J = 8.71 Hz, 2H), 7.80 (t, J= 7.98 Hz, 1H), 7.68 
(m, 2H); 6.93 (d, J = 9.11 Hz, 2H), 5.77 (s, 2H), 4.90 (s, 2H), 3.72 (t, 1H), 3.62 (m, 
8H). 
 
4.2.2 Synthesis of azide hemicyanine dye 
4.2.2.1 Synthesis of propane diazide 
 
This synthesis was done after a procedure described by Ciampi et al. (142). Briefly:  
1,3-dibromopropane (5.0 g, 24.8 mmol) was diluted in DMF (80 mL). Sodium azide 
(5.0 g, 76.9 mmol) was added in one portion under argon. The reaction mixture was 
heated to 65° C and the reaction was continued for 48 h under argon. Afterwards the 
reaction mixture was cooled to room temperature and diluted with diethyl ether (200 
mL). The resulting suspension was washed with water (20 mL) and two times with 
brine (50 mL) and then dried over NaSO4. Removal of sodium sulfate by filtration and 
subsequent evaporation gave yellow oil. The crude product was further purified using 
column chromatography (silica gel) with elution by hexane to give propane diazide  
as colorless oil (2.5 g, 80,11%). 1H NMR (300 MHz, CDCl3) δ: 1.80 (q, 2H), 3.35 (t, 
4H, J = 6.5 Hz). 
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4.2.2.2 Synthesis of azide hemicyanine dye by CuAAC  
 
 
Alkyne hemicyanine dye (2-[2-(4-Dihydroxyethylamino-phenyl)-vinyl]-3-prop-2-ynyl-
benzothiazol-3-ium bromide) (25 mg, 54 µmol) was diluted in DMSO (1ml). Propane 
diazide was added in one portion (540 µmol, 110 mg). Reaction was started by 
addition of click solution C (30 µl). Preparation of click solution is described in section 
3.5. The reaction mixture was stirred 2 hours at 80° C. After cooling to room 
temperature the mixture was precipitated in MTBE (50 ml) three times. The residue 
was purified by DCVC. First the column was washed with ethylacetate/MetOH (9:1, 
v/v) followed by a washing step with acetone/methanol (9/1, v/v) and elution using 
acetone/water (1:1, v/v). Most of the acetone was removed by evaporation and the 
residue was lyophilized. This gave a dark purple fluffy solid (39.8 mg, 63 %). MS 
(FAB+, 8 kV) calcd for C25H29N8O2S [M]+ 505.52, found 505.2 . 1H NMR (500 MHz, 
[d6]DMSO)  8.30 (d, J = 7.82 Hz, 1H), 8.12 (m, 2H), 7.90 (d, J = 8.71 Hz, 2H), 7.80 (t, 
J= 7.98 Hz, 1H), 7.68 (m, 2H); 6.93 (d, J = 9.11 Hz, 2H), 6.38 (s, 2H), 4.90 (s, 2H), 
4.42 (t, 2H), 3.62 (m, 8H), 3.37 (m, 2H), 1.81 (m, 2H). 
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4.2.3 Synthesis of N-propargyl maleimide 
 
 
 
N-Propargyl maleimide was synthesized quite similar as described elsewhere (143). 
In short: A saturated aqueous solution of sodium bicarbonate (40 ml), propargylamine 
(330 µl, 4.84 mmol) was dissolved and cooled on an ice bath. Afterwards N-(methoxy 
carbonyl) maleimide (751 mg, 4.81 mmol) was added in portions over 20 min under 
vigorous stirring. This mixture was stirred for 30 min at 0° C, followed by 45 min at 
room temperature. Subsequently the product was extracted with CH2Cl2 (3 × 50 mL). 
The organic phase was dried over Na2SO4 and the crude product was purified by 
silica gel column chromatography with using EtOAc/heptane (1:2) as solvent.  
Evaporation of the solvent gave colorless oil (279 mg, 43% yield). 1H NMR (500MHz, 
CDCl3): 6.76 (s, 2H); 4.30 (d, J = 2.5 Hz, 2H); 2.22 (t, J = 2.5 Hz, 1H). 
 
4.2.4 Synthesis of N-succininimidyl-3-(2-pyridyldit hio)-propionate 
(SPDP) 
SPDP was synthesized quite similar to the method described elsewhere (144). All 
modifications are announced in the following section. 
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4.2.4.1 Synthesis of 3-(Pyridin-2ylsulfanyl)-propio nic acid 
 
 
Dithiopyridine (3.77 g, 17.11 mmol) was diluted in 30 ml EtOH and 0.4% acetic acid. 
A solution of 3-mercaptopropionic acid (0.9 g, 8.48 mmol, 737 µl) in 20 ml EtOH and 
0.4 % acetic acid was added dropwise over one hour. 2 hours later the solvent was 
removed on an evaporator. The resulting oil was purified by DCVC using basic 
aluminia as stationary phase (diameter 4 cm, h=7 cm). After the column was 
preconditioned with CHCl3 and loaded, the crude product was washed with 
CHCl3/MeOH 8/2 until the collected fractions were colorless. Afterwards the product 
could be eluted by addition of 4% acetic acid to the former solvent mixture. Fractions 
were collected and the solvent was removed by evaporation (1.67 g, 91%). 1H NMR 
(500 MHz, [CD3OD) 8.40 (ddd, J = 4.9/1.8/0.9 Hz, 1H), 7.77-7.89 (m, 2H), 7.20-7.26 
(m, 1H); 3.04 (t, J = 6.9 Hz, 2H), 2.71 (t, J= 6.8 Hz, 2H). 
 
4.2.4.2 Synthesis of SPDP 
 
 
3-(Pyridin-2ylsulfanyl)-propionic acid (1.643 g, 7.634 mmol) was dissolved in dry 
CH2Cl2. N-hydroxysuccinimide (1.0 g, 8.68 mmol) was added in one portion. After the 
suspension was completely dissolved,  N,N′-Dicyclohexylcarbodiimide (DCC) (1.7505 
g, 8.688 mmol) was added. 4 hours later the side product Dicyclohexylurea (DCU) 
was filtered off and the solvent was removed by evaporation. The yellowish solid was 
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purified by DCVC (diameter 4 cm, h=7 cm) using silica gel as stationary phase and a 
gradient of 0-15% MeOH in CH3Cl (50 ml fractions). After recrystallization in EtOH 
the pure product, a white solid was obtained (1.48 g, 62%). 1H NMR (500 MHz, 
[CDCl3) 8.48-8.51 (ddd, J = 4.7/1.3/1.2 Hz, 1H), 7.64-7.69 (m, 2H), 7.09-7.14 (m, 
1H); 3.09 -3.15 (m, 2H), 3.04 -3.09 (m, 2H), 2.84 (s, 4H). 
 
4.2.5 Synthesis of MAM linker  
 
The synthesis of MAM linker (6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(4-(((2,5-
dioxo-2,5-dihydrofuran-3-yl)methyl)thio)phenyl)hexanamide) was done according to 
the method of Blättler et al. (134).  
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4.2.6 Synthesis of AzMMMan linker 
  
The azidomethyl-methylmaleic anhydride linker (AzMMMan) was synthesized from 
dimethylmaleic anhydride as precursor very straightforward in two simple reaction 
steps: a) radical substitution with N-bromosuccinimide resulting in 2, followed by b) 
Finkelstein reaction with sodium azide. 
 
4.2.6.1 Synthesis of 3-(Bromomethyl)-4-methyl-2,5-f urandione 
 
This compound was synthesized according to the procedure described elsewhere 
(145) with minor modifications. Dimethylmaleic anhydride (5.04 g, 50 mmol), N-
bromosuccinimide (14.24 g, 100 mmol), and benzoyl peroxide (200 mg, 0.83 mmol) 
where dissolved in carbon tetrachloride (250 mL). This mixture was gently refluxed 
for 5 h in a 500 mL round-bottom flask. Afterwards the reaction mixture was allowed 
to cool to room temperature and an additional amount of benzoyl peroxide (200 mg, 
0.83 mmol) was added. The refluxing was continued 5 h more. After cooling to room 
temperature the residue was filtered and washed two times with carbontetrachloride 
(25 ml). Subsequently the organic phase was washed two times with water (100 mL) 
and brine (100 mL). The organic layer was dried over Na2SO4 and concentrated in 
vacuo to result in yellow oil. This oil was first purified by chromatography on a silica 
gel column and eluted with a mixture of petroleum ether/ethyl acetate (8:2). Finally 
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the residue was distilled under high vacuum (120-125° C, 2 mm) to get pure product 
(3.9 g, 56% yield).1H NMR (400 MHz, CDCl3) 4.17 (s 2H), 2.17 (s 3H). 
 
4.2.6.2 Synthesis of 3-(Azidomethyl)-4-methyl-2,5-f urandione 
 
3-(Bromomethyl)-4-methyl-2,5-furandione (310.5 mg, 1.5 mmol) was dissolved in 
acetone (10 ml). Sodium azide (97.5 mg, 1.5 mmol) was added in one portion. The 
suspension was stirred over night at room temperature. After filtering the solvent was 
evaporated. The remaining oil was dissolved in ethyl acetate (20 ml) and washed 
with water (20 ml). Afterwards the organic layer was washed with 20 ml brine and 
dried over Na2SO4. Concentration in vacuo, followed by chromatographic purification 
over a silica gel column using hexane/ethyl acetate (7:3) as mobile phase gave pure 
product (220 mg, yield 88%).1H NMR (500 MHz ,CDCl3) 4.29 (q, J = 1.01 Hz, 2H), 
2.17 (t, J = 1.01 Hz 3H). 13C NMR (100 MHz, [d6] acetone) δ 9.09, 43.15, 137.23, 
144.51, 165.24, 165.93. IR νmax 2101, 1759, 1679 cm-1. MS (70 eV, DEI+) calcd for 
C6H5N3O3 [M]+ 167.12, found 166.99. 
 
4.2.7 Synthesis of PentyneMMan linker 
 
The 3-methyl-4-(pent-4-yn-1-yl)furan-2,5-dione linker (PentyneMMan) was 
synthesized from 3-(Bromomethyl)-4-methyl-2,5-furandione anhydride by a Grignard 
reaction with 3-butynyl-1-magnesium bromide. 
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4.2.7.1 Synthesis of 3-butynyl-1-magnesium bromide  
 
This reaction was done analog as described elsewhere (146). Briefly: First the 
reaction flask was charged with ZnBr2 (120 mg, 4 mol %, 0.53 mmol) and Mg (650 
mg). Afterwards the flask was heated under vacuum and flushed with argon. Now 
diethylether (10 mL) and propargyl bromide (1.0 mL, 13 mmol) in Et2O (8 mL) were 
added dropwise over a period of 40 minutes. Subsequently after the addition, 
exothermic reaction started and the mixture was cooled to 0° C (ice water). The 
mixture was stirred at the same temperature for further 1 h. This gave a greenish 
supernatant and pulverized Mg precipitates. The concentration of the supernatant 
was 0.52 M. This was determined by titration using methyl orange as an indicator 
(74% yield). 
 
4.2.7.2 Synthesis of 3-methyl-4-pentynyl-furan-2,5- dion 
 
3-(Bromomethyl)-4-methyl-2,5-furandione anhydride (410 mg, 2 mmol) and CuJ (38 
mg, 0.2 mmol) were dissolved in Et2O (10 mL). Now HMPA (4 ml) was added. The 
reaction flasc was flushed with argon. Reaction was started by dropping in a solution 
of 3-butynyl-1-magnesium bromide (0.52 M) from the reaction described above. 
Reaction was continued for 15 minutes over an ice bath. Now the reaction mixture 
was allowed to warm to room temperature and stirring was continued overnight. The 
resulting pink suspension was diluted with Et2O (15 mL). Subsequently sulphuric acid 
(4 M, 10 ml) were added. The precipitations dissolve and the solution is turning 
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brown. The water phase was extracted three times with Et2O (15 mL). Afterwards the 
combined organic phases were washed two times with water (20 mL) and then with 
brine (20 ml). Now the organic phase was dried with Na2SO4 filtered and solvent was 
removed by evaporation. The crude product purified over DCVC (diameter 4 cm, h=7 
cm) with a step gradient from 0-50% EtAc in n-hexane (2.5 % steps, 20 ml fractions). 
After the solvent was removed colorless oil was obtained (113 mg, 32 %). TLC: Rf = 
0.44 (n-heptane/EtAc =3/1). 1H NMR (500 MHz, CDCl3) 2.56 (m, 2H), 2.19 (m, 2H), 
2.05 (s, 3H), 1.962 (m, 2H), 1.77 (m, 2H) 13C NMR (100 MHz, CDCl3) δ 9.56, 18.023, 
23.20, 25.86, 69.85, 82.66, 141.54, 143.52, 165.68, 165.99. IR νmax 3291, 2937, 
2118, 1762, 1699, 1624 cm-1. MS (70 eV, DCI+) calcd for C10H10O3 [M]+ 178.18, 
found 179.1. 
 
4.3 Cloning, heterologous expression and purificati on of 
nlsEGFP and HIV-TAT-nlsEGFP 
The plasmid containing a gene for EGFP, tagged with a nuclear localization 
sequence (derived from SV 40 large T antigen), was kindly provided by M. Cristina 
Cardoso (TU Darmstadt, Germany). The coding region of the plasmid was amplified 
with PCR reaction using following primers:  
forward: 5´-GTTGATGAATTCCCGAAGAAGAAGCGCAAAGTA-3`;  
reverse: 5`-TCAACTAAGCTTCTTGTAAAGCTCGTCCATGCC-3`. 
This gene was cloned into Novagen pET 23a (+) vector (Merck4biosciences, 
Darmstadt, Germany).  By the common calciumchloride method, this plasmid was 
transformed into E. coli BL21(DE3)plysS (Novagen, Merck4biosciences, Darmstadt , 
Germany). Under constant shaking in TB medium (37° C), the cells were grown to an 
optical density of 0.75 (600nm). Protein expression was induced with isopropyl β-D-
1-thiogalactopyranoside (Biomol, Hamburg, Germany) (final concentration 1mM) and 
expression was continued for another 16 hours. After ultrasonic cell lysis the 
nlsEGFP was purified by nickel chromatography using a gradient from binding buffer 
(50 mM sodium hydrogenphosphate, 300 mM sodium chloride, 20 mM imidazole) to 
elution buffer (50 mM sodium hydrogenphosphate, 500 mM sodium chloride, 250 mM 
imidazole). The protein was dialysed over night at 4° C against PBS buffer (pH 7.3) 
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using a dialysis membrane (14000 MWCO) from Carl Roth (Karlsruhe, Germany). 
Finally the nlsEGFP was concentrated with Amicon Ultra centrifugal filter units 
(MWCO 10,000). Transformation, protein expression and purification of the PTD 
bearing homolog were done in the same way. Following primers encoding for HIV-
TAT sequence were annealed and cloned into the vector described above.  
Sense: 5`AGCTTGGTTATGGGCGCAAAAAACGCCGTCAGCGCCGTCGGGGCC3` 
Antisense: 5`TCGAGGCCCCGACGGCGCTGACGGCGTTTTTTGCGCCCATAACCA 
3` 
 
4.4 Modification of proteins with crosslinkers 
4.4.1 Modification with SPDP 
4.4.1.1 Modification of nlsEGFP with SPDP 
nlsEGFP (3 mg, 0.095 µmol) was diluted in PBS buffer (1 ml; pH 7.3, 1 mM EDTA). 
Then SPDP (Succinimidyl 3-(2-pyridyldithio) propionate) was dissolved in DMSO (50 
µl; 1.14 µmol) and added to above protein solution. After incubation (2 h; 20°C), not 
conjugated linker was removed by size exclusion chromatography (Sephadex G25 
superfine) using PBS buffer (pH 7.3, 1 mM EDTA) as mobile phase. The modified 
protein was concentrated with Amicon Ultra centrifugal filter units (MWCO=10,000; 
Millipore (Billerica, MA)). Protein concentration was quantified by measurement of the 
absorbance at a wavelength of 488 nm using an extinction coefficient of 55000 M-
1cm-1. The ratio of linker to protein could be calculated, after reducing a sample of the 
modified protein with DTT (dithiothreitol) and determination of the change in 
absorbance (343 nm; 8080 M-1cm-1). 
 
4.4.1.2 Modification of ß-galactosidase with SPDP 
ß-galactosidase (3 mg, 0.026 µmol) was diluted in PBS buffer (1 mL; pH 7.3, 1 mM 
EDTA). Then SPDP (succinimidyl 3-(2-pyridyldithio)propionate) was dissolved in 
DMSO (50 µl; 0.775 µmol) and added to above protein solution (30-fold molar excess 
compared to ß-galactosidase). After incubation (2 h; 20° C), unconjugated linker was 
removed by size exclusion chromatography (Sephadex G25 superfine) using PBS 
Material and Methods  44 
buffer (pH 7.3, 1 mM EDTA) as mobile phase. The modified protein was concentrated 
with Amicon Ultra centrifugal filter units (MWCO 10,000; Millipore (Billerica, MA)). 
The protein concentration was determined at 280 nm using a molar extinction 
coefficient of 210000 M-1cm-1. The ratio of linker to protein could be calculated, after 
reducing a sample of the modified protein with DTT (dithiothreitol) and determination 
of the change in absorbance (343 nm; 8080 M-1cm-1).  
 
4.4.2 Modification of nlsEGFP with succinimidyl-4-( N-
maleimidomethyl) cyclohexane-1-carboxylate (SMCC) 
nlsEGFP (2 mg, 0.063 µmol) was diluted in PBS buffer (1 ml, pH 7.3) and SMCC (0.3 
mg, 0.951 µmol) dissolved in DMSO (50 µl) was added. After an incubation time of 2 
hours at room temperature, the reaction mixture was passed through a Sephadex G 
25 superfine size exclusion column. The purified protein was concentrated with 
Amicon Ultra centrifugal filter units (MWCO 10,000). 
 
 
4.4.3 Modification of nlsEGFP with MAM linker 
nlsEGFP (5 mg, 0.158 µmol) was dissolved in Hepps Puffer (950 µl, 0.5 M, pH 9.0). 
Afterwards MAM linker (5 mg, 11.66 µmol) was diluted in DMSO (50 µl) and dropped 
slowly to the protein solution. Incubation (2 h) under constant stirring (20° C) was 
followed by removal of non-coupled linker. This was performed by size exclusion 
chromatography using PBS buffer (pH 8.0) as mobile phase. The modified protein 
was concentrated with Amicon Ultra centrifugal filter units (MWCO 10,000; Millipore 
(Billerica, MA)). The concentration of the modified nlsEGFP was quantified by 
measuring the absorbance (488 nm) using an extinction coefficient of 55000 M-1cm-1. 
 
4.4.4 Modification of HSA with PentyneMMan linker 
Human serum albumin (5 mg, 0.075 µmol) was dissolved in 500 µl Hepps buffer (0.5 
M, pH 9.0). Then PentyneMMan linker (5 mg, 0.028 mmol) was diluted in acetonitrile 
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(50 µl) and slowly dropped into the protein solution. After incubation for 2 h under 
constant stirring at room temperature not conjugated linker was removed by size 
exclusion chromatography using PBS buffer (pH 8.0) as mobile phase. The modified 
protein was concentrated with Amicon Ultra centrifugal filter units (MWCO 10,000; 
Millipore (Billerica, MA)). The concentration of the modified HSA was quantified by 
measurement the absorbance at a wavelength of 280 nm using an extinction 
coefficient of 41440 M-1cm-1. 
 
4.4.5 Modification with AzMMMan linker 
4.4.5.1 Modification of Melittin 
Melittin peptide (2 mg, 2893.6 g mol-1, 0.691 µmol) was dissolved in a mixture of 
acetonitrile and Hepps buffer (0.5 M, pH 9.0) (1/2 v/v, 1 ml). Immediately after 
hydrolysis, N-ethylmaleimide (1 µmol, 0.125 mg) dissolved in acetonitrile (50 µl) was 
added. After 10 minutes at room temperature AzMMMAn crosslinker (7.5 mg, 45 
µmol) was added and aggitated for 2 hours at 20° C. The reaction buffer was diluted 
in PBS buffer (add 5 ml, pH 8.5) and concentrated via ultrafiltration (Vivaspin2, 
Vivascience, Hannover, Germany MWCO 1000).  Thereafter the reaction mixture 
was passed over a SEC G25 size exclusion column using 2.5 mM ammonium 
carbonate buffer (pH adjusted to 8.0) as eluent. The peptide containing fraction was 
lyophylised. 
 
4.4.5.2 Modification of HSA 
Human serum albumin (5 mg, 0.075 µmol) was dissolved in 500 µl Hepps buffer (0.5 
M, pH=9.0). Then AzMMMan (5 mg, 0.03 mmol) was diluted in acetonitrile (50 µl) and 
slowly, dropped into the protein solution. After incubation for 2 h under constant 
stirring at room temperature not conjugated linker was removed by size exclusion 
chromatography using PBS buffer (pH 8.0) as mobile phase. The modified protein 
was concentrated with Amicon Ultra centrifugal filter units (MWCO 10,000; Millipore 
(Billerica, MA)). The concentration of the modified HSA was quantified by 
measurement the absorbance at a wavelength of 280 nm using an extinction 
coefficient of 41440 M-1cm-1. 
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4.4.5.3 Modification of nlsEGFP 
The conjugation was performed analogous to the method described above for the 
modification of HSA. Briefly: nlsEGFP 5 mg (0.158 µmol) was dissolved in Hepps 
Puffer (950 µl, 0.5 M, pH 9.0). Afterwards AzMMMan linker (5 mg, 0.03 mmol) was 
diluted in acetonitrile (50 µl) and dropped slowly to the protein solution. Incubation (2 
h) under constant stirring (20° C) was followed by removal of non-coupled linker. This 
was performed by size exclusion chromatography using PBS buffer (pH 8.0) as 
mobile phase. The modified protein was concentrated with Amicon Ultra centrifugal 
filter units (MWCO 10,000; Millipore (Billerica, MA)). The concentration of the 
modified nlsEGFP was quantified by measuring the absorbance (λ 488 nm) using an 
extinction coefficient of 55000 M-1cm-1. 
 
4.4.5.4 Modification of ß-galactosidase  
The conjugation was performed very similar to the method described above for the 
modification of HSA. Briefly: ß-Gal 5 mg (0.043 µmol) was dissolved in Hepps Puffer 
(975 µl, 0.25 M, pH 8.5). Afterwards AzMMMan linker 3 (5 mg, 0.03 mmol) was 
diluted in acetonitrile (25 µl) and dropped slowly to the protein solution. Incubation (2 
h) under constant stirring (20° C) was followed by removal of non-coupled linker. This 
was performed by size exclusion chromatography using PBS buffer (pH 8.0) as 
mobile phase. The modified protein was concentrated with Amicon Ultra centrifugal 
filter units (MWCO 10,000; Millipore (Billerica, MA)). The concentration of the 
modified ß-Gal was quantified by measuring the absorbance (λ 280 nm) using an 
extinction coefficient of 210000 M-1cm-1. 
 
4.5 Coupling of carriers, dyes and PEG to the prote ins 
4.5.1 Coupling of G3 PPI to nlsEGFP via EDC 
G3 PPI (50 mg, 0.03 mmol) was diluted in H2O (1ml). After complete dissolution pH 
was adjusted to 5.0 with water diluted hydrochloric acid (1 M). nlsEGFP (1 mg) 
diluted in 100 µl PBS buffer was added. The reaction was started by the addition of 
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EDC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, final 
concentration 0.1 mg/ml) and continued under constant stirring at room temperature 
for 16 hours. The dendrimer modified nlsEGFP was purified over size exclusion 
chromatography using PBS buffer (pH 7.4) as mobile phase. Afterwards the product 
was concentrated using Amicon Ultra centrifugal filter units (MWCO 10,000). 
 
4.5.2 Coupling of G3 PPI to nlsEGFPx5SPDP via a red ucible 
disulfide bond 
G3 PPI was diluted in PBS buffer (10 mg, 6 µmol, 1 ml). pH was adjusted to 7.4 with 
water diluted hydrochloric acid (1 M). SPDP (8 µmol) diluted in 100 µl DMSO was 
added in one portion. After reaction for 2 hours at room temperature the protected 
thiol group was reduced by the addition of DTT (0.01 mmol, 1.5 mg) and further 
stirring for 30 minutes. The reaction product was purified over size exclusion 
chromatography using 0.01 M HCl as mobile phase and subsequently lyophylized. 
SPDP modified nlsEGFP (1 mg, 0.0317 µmol) was diluted in Hepps buffer (1 ml, 0.5 
M pH 8.0) and 10-fold molar excess of thiol bearing G3 PPI dendrimer (compared to 
covalently bound linker) (0.32 µmol, 0.54 mg) was added and reacted for one hour. 
The reaction product was purified over SEC using PBS buffer (pH 7.4) as mobile 
phase. 
 
4.5.3 Coupling of 386 to nlsEGFPx5SPDP 
SPDP modified nlsEGFP (1 mg, 0.0317 µmol) was diluted in Hepps buffer (1 ml, 0.5 
M pH 8.5) and 2-fold molar excess of oligomer 386 (compared to covalently bound 
linker) (0.32 µmol, 1.95 mg, 39 µl) which was pre-dissolved in water (50 mg/ml), was 
added for the modification of nlsEGFP. Thereafter pH was adjusted to 7.5 with 
aqueous HCl (1 M). The product was purified, after 1 hour incubation (20° C) by 
Amicon Ultra centrifugal filter units (MWCO 10,000; ×3 washing steps with PBS 
buffer, 1 mM EDTA, pH 7.3).  
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4.5.4 Coupling of 386 to ß-galactosidasex8SPDP 
SPDP modified ß-galactosidase (1 mg,  0.0086 µmol) was diluted in Hepps buffer (1 
ml, 0.5 M pH 8.5) and 5-fold molar excess of oligomer 386 (compared to covalently 
bound linker) (0.34 µmol, 2.1 mg, 42 µl) which was pre-dissolved in water (50 mg/ml), 
was added for the modification of nlsEGFP. Thereafter pH was adjusted to 7.5 with 
aqueous HCl (1 M). The product was purified, after 1 hour incubation (20° C) by 
Amicon Ultra centrifugal filter units (MWCO 10,000; ×3 washing steps with PBS 
buffer, 1 mM EDTA, pH 7.3). 
 
4.5.5 Coupling of 386 to SMCC-nlsEGFP 
SMCC modified nlsEGFP (1 mg, 0.032µmol) was diluted in Hepps buffer (1 ml, 0.5 M 
pH 8.5). Then a dilute aqueous solution (30 µl, 50 mg/ml) of oligomer 386 (Mw 6165.9 
gmol-1) was added (0.24 µmol). The pH was adjusted to 7.5 with aqueous HCl (1 M). 
After incubation for 1 hour at room temperature the product was isolated by Amicon 
Ultra centrifugal filter units (MWCO 10,000) (×2 washing steps with PBS buffer pH 
7.3).  
 
4.5.6 Coupling of 386 to AzMMMan-nlsEGFP 
Oligomer 386 (1.5 mg, 0.24 µmol, containing within the sequence three mol 
equivalent cysteine mercapto groups) was diluted in Hepps buffer (1 ml, 0.5 M, pH 
8.5). Subsequently dibenzylcyclooctyne-PEG4-maleimide (0.49 mg, 0.72 µmol) 
diluted in DMSO (100 µl) was added. Afterwards the pH was adjusted to 8.0. This 
mixture was given in one portion to AzMMMan-nlsEGFP (1 mg, 0.032 µmol) diluted 
in Hepps buffer (1 ml, 0.5 M, pH 8.0). After 4 hours at 20°C non-conjugated polymer 
was removed by centrifugation steps with Amicon Ultra centrifugal filter units (MWCO 
10,000) (×2 washing steps with PBS buffer pH 7.3). 
 
4.5.7 Coupling of TMR labelled-386 to AzMMMan-nlsEG FP 
386 (20 mg, 3.244 µmol) was dissolved in DMSO (400 µl) and TMRM (1.56 mg, 
3.244 µmol), dissolved in DMSO (400 µl) was added. After one hour at room 
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temperature, dibenzylcyclooctyne-PEG4-maleimide (4.38 mg, 6.48 µmol) diluted in 
DMSO (200 µl) was added and stirred for one hour. This was dropped slowly under 
stirring to AzMMMan-nlsEGFP (10 mg diluted in 10 ml 0.5 M Hepps buffer pH 8.5). 
After 4 hours at 20° C non-conjugated polymer was removed by centrifugation steps 
with Amicon Ultra centrifugal filter units (MWCO 10,000) (×2 washing steps with PBS 
buffer pH 7.3).  
 
4.5.8 Coupling of 386 to AzMMMan-ß-galactosidase 
Oligomer 386 (1.5 mg, 0.24 µmol, containing within the sequence three mol 
equivalent cysteine mercapto groups) was diluted in Hepps buffer (1 ml, 0.5 M, pH 
8.5). Subsequently DBCO-PEG4-maleimide (0.49 mg, 0.72 µmol) diluted in DMSO 
(100 µl) was added. Afterwards the pH was adjusted to 8.0. This mixture was given in 
one portion to AzMMMan-ß-Gal (1 mg, 0.0086 µmol) diluted in Hepps buffer (1 ml, 
0.5 M, pH 8.0). After 4 hours at 20° C non-conjugated polymer was removed by 
centrifugation steps with Amicon Ultra centrifugal filter units (MWCO 10,000) (×2 
washing steps with PBS buffer pH 7.3). 
 
4.5.9 Coupling of poly(ethylene glycol) (PEG) 
4.5.9.1 Coupling of PEG 5000 to AzMMMan-nlsEGFP 
Poly(ethylene glycol) methyl ether thiol (average Mw 5000 g/mol, 2 mg, 0.4 µmol) was 
dissolved in PBS buffer (80 µl, pH 8,0). Subsequently N-propargyl maleimide (0.4 
µmol) diluted in acetonitrile (20 µl) was added. This mixture was dropped into 
AzMMMan-HSA (0.5 mg, 7.5 nmol) diluted in PBS (900 µl, pH 8.0). The click reaction 
was initiated by adding click solution C (30 µl). Click solution C was freshly prepared 
as described in section 3.5.  After incubation for 3 h at 20° C the product was purified 
via ultrafiltration (Amicon Ultra centrifugal filter units (MWCO 10,000), ×2 washing 
steps with PBS buffer pH 8.0). 
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4.5.9.2 Coupling of TMR labelled PEG to AzMMMan-nls EGFP 
PEG dithiol (Mw 8000, 10 mg, 1.25 µmol) was dissolved in DMSO (800 µl) and  
Tetramethylrhodamine-5-maleimide (TMRM) (0.6 mg, 1.25 µmol), dissolved in DMSO 
(100 µl) was added. After one hour at room temperature, N-propargyl maleimide 
(0.17 mg, 1.25 µmol) diluted in DMSO (100 µl) was added and stirred for one hour. 
200 µl of this solution was dropped slowly under stirring to AzMMMan-HSA (1 mg, 
0.015 mol, diluted in 1.8 ml PBS buffer pH 8.0). The click reaction was started by 
addition of click reaction c (30 µl). Click solution C was freshly prepared as described 
in the section buffers and solutions. After 4 hours at 20° C, non-conjugated PEG 
polymer and dye were removed by centrifugation steps with Amicon Ultra centrifugal 
filter units (MWCO 10,000) (×2 washing steps with PBS buffer pH 7.3), yielding the 
TMR-PEG-HSA conjugate. 
 
4.5.10 Coupling of alkyne hemicyanine dye to AzMMMa n-HSA 
AzMMMan-HSA (5 mg, 0.075µM) was diluted in PBS buffer (1.5 ml, pH 8.0). Alkyne 
dye (0.375 mg, 0.99 µmol) was diluted in DMSO (50 µl) and dropped into the protein 
solution. Reaction was started by addition of click solution C (30 µl). Click solution C 
was freshly prepared as described in the section buffers and solutions. After 3 h of 
incubation at 20°  C the reaction batch was purified with Amicon Ultra centrifugal filter 
units (MWCO 10,000) (two washing steps with PBS buffer pH 8.0), followed by an 
additional purification step over size exclusion chromatography using PBS buffer (pH 
8.0) as mobile phase. 
 
4.5.11 Coupling of phosphine dye DyLight 488 to AzM MMan-HSA 
DyLight 488, a phosphine containing dye (Thermo Fisher Scientific, Germany) (0.1 
mg, 0.09 µmol) was dissolved in DMSO (20 µl). This was added to AzMMMan-HSA 
(2 mg, 0.03 µmol, diluted in 230 µl PBS buffer pH 8.5) resulting in an end 
concentration of 8 mg protein/ml. After 4 h incubation at 37° C the labeled HSA was 
purified over SEC (G25 superfine) with PBS buffer (pH 8.5) as eluent. 
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4.5.12 Coupling of azide dye to PentyneMMan-HSA 
PentyneMMan-HSA (5 mg, 0.075 µM) was diluted in PBS buffer (1.5 ml, pH 8.0). 
Azide dye (0.375 mg, 0.64 µmol) was diluted in DMSO (50 µl) and dropped into the 
protein solution. Reaction was started by addition of click solution C (30 µl). Click 
solution C was freshly prepared as described in the section buffers and solutions. 
After 3 h of incubation at 20° C the reaction batch was purified with Amicon Ultra 
centrifugal filter units (MWCO 10,000) (two washing steps with PBS buffer pH 8.0), 
followed by an additional purification step over size exclusion chromatography using 
PBS buffer (pH 8.0) as mobile phase. 
 
4.5.13 Coupling of folic acid and melittin to AzMMM an-EGFP 
 
Scheme 4.2: Synthesis of a polycation-free protein transduction shuttle.  
Folic acid-PEG-lysine (5 mg, 2.9 µmol) was diluted in 400 µl of a 1/1 mixture of 
Hepps (0.25 M, pH 8.5) and DMSO. After dissolution DBCO-NHS ester (2.9 µmol, 
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1.25 mg) diluted in DMSO (100 µl) was added. The reaction was continued for 2 
hours and the mixture was purified by dialysis against PBS buffer (pH 8.5) over night. 
A dialysis membrane with a MWCO of 1000 Da (Carl Roth (Karlsruhe, Germany)) 
was used. Afterwards it was filed up to 1ml with PBS (pH 8.5). Melittin (0.5 mg, 0.169 
µmol) was diluted in PBS containing 30% acetonitrile (200µl). Now 
dibenzylcyclooctyne-PEG4-maleimide (0.11 mg, 0.169 µmol) diluted in DMSO (50 µl) 
was added dropwise and stirred for 30 minutes. Meanwhile AzMMMan-nlsEGFP (1 
mg, 0.032 µmol) was diluted in PBS buffer (1 ml, pH 8.5). To the protein solution was 
added a threefold surplus of the folic acid conjugate ( 0.1 µmol, 35 µl) and reacted for 
two hours at room temperature. Thereafter a 5 fold excess of the melittin conjugate 
was added (0.16 µmol, 236 µl) and reaction was continued for another two hours. 
Later the modified protein was purified over size exclusion chromatography SEC G25 
superfine with PBS buffer (pH 8.5) as eluent. 
 
4.5.14 Coupling of transduction oligomer 71 to MAM- EGFP 
MAM modified nlsEGFP (1 mg, 0.032 µmol) was diluted in Hepps buffer (1 ml, 0.5M 
pH 8.5). Then a dilute aqueous solution of transduction oligomer 72 (Mw 2247.25 
gmol-1) was added (0.064 µmol). The pH was adjusted to 7.5 with aqueous HCl (1 
M). After incubation for 1 hour at room temperature, precipitated protein was 
separated by centrifugation. The supernatant was purified by dialysis against PBS 
buffer (pH 7.4, MWCO 15000 Da) over night. 
 
4.6 Characterization of new acid labile crosslinker s 
4.6.1 Determination of the degree of protein modifi cation  
Samples of HSA (Mw 66478 g mol
-1, 5 mg, 0.075µM) were reacted with the azido-
dimethylmaleic anhydride linker (compound 3, Scheme 5.8) as described above. But 
this time varying amounts of AzMMMan diluted in acetonitrile (50 µl) were added 
(end concentrations of 2.0, 1.8, 1.6, 1.4, 1.2, 1.0, 0.8, 0.6, 0.4, 0.2 mM). After 
purification the AzMMMan modified HSA (compound 4, Scheme 5.8) was reacted 
with an excess of the water soluble alkyne dye (0.375 mg, 0.99 µmol) as described 
above to result in compound 7 (Scheme 5.8). The amount of AzMMMan groups 
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incorporated in HSA could be determined by quantifying the amount of dye coupled 
to the protein. This was done by following procedure. A sample of the labeled HSA 
was taken and the dye was cleaved off from the protein by incubation in an equal 
volume acetate buffer (0.5 M, pH 3.0) for 5 hours at 37° C. Thereafter the solution 
was neutralized with Tris buffer (1 M, pH 9.0) and the absorbance of the dye was 
measured at a wavelength of 530 nm (ε 35000 M-1 cm-1). After purification over a size 
exclusion column with PBS (pH 7.3) as eluent, the protein concentration was 
determined by measuring the HSA absorbance at 280 nm using an extinction 
coefficient of 41440 M-1cm-1.  
 
4.6.2 Determination of the acid catalyzed release o f linker from the 
protein 
This experiment was done similar to the method described above for the 
determination of AzMMMAn groups incorporated into HSA. Dye labelled HSA 
(compound 7, Scheme 5.8) was acidified to the required pH with acetic acid and 
incubated in the same volume of citric acid-phosphate (0.1 M) buffer. Thus samples 
having final pH values of 8.5, 7.3, 6.0, 5.0 and 4.0 were obtained. These samples 
were incubated at 37° C. At different time points samples were withdrawn. The 
amount of released dye was determined, after purification over a size exclusion 
column, by measuring the absorbance of the dye still coupled to the protein. For the 
comparative release between dye coupled via Staudinger Ligation and dye linked via 
CuAAc the incubation was done at 20° C for 16 h. The amount of Dylight was 
determined using an extinction coefficient of 70000 M-1cm-1 at a wavelength of 493 
nm. 
 
4.6.3 Serum stability assay 
For the serum stability assay experiments were done following the same procedure 
as described above in 4.6.2. After incubation against PBS buffer (pH 7.4) containing 
30% fetal bovine serum at 37 °C for different time intervals samples were withdrawn 
purified and analyzed. Each experiment was done in triplicates. 
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4.6.4 Release of PEG from HSA conjugate  
Polyethylene glycol modified HSA (compound 8, Scheme 5.8) was dialyzed against 
citric acid-phosphate buffers of different pH values (0.1 M, pH: 8.5, 7.3, 6.0, 5.0, 4.0) 
for 16 hours at 37° C using a 14000 MWCO dialysis membrane from Carl Roth 
(Karlsruhe, Germany). Afterwards the solutions were neutralised using sodium 
hydroxide (1 M). Samples of protein (about 20 µg) were loaded on a 12.5% SDS-
PAGE gel. The gel ran for 2 hours at 160 V. After electrophoresis the gel was stained 
with comassie solution (45/45/10 water/methanol/acetic acid and 0.5% comassie 
brilliant blue G250). Then the gel was washed several times with an aqueous solution 
of acetic acid (7.5% v/v) and ethanol (20% v/v). 
 
4.6.5 Release kinetics of TMR-labeled PEG from HSA conjugate  
To determine the detailed release kinetics, PEG was labeled with 
Tetramethylrhodamine-5-maleimide (TMRM). Briefly: PEG dithiol (Mw 8000, 10 mg, 
1.25 µmol) was dissolved in DMSO (800 µl) and TMRM (0.6 mg, 1.25 µmol), 
dissolved in DMSO (100 µl) was added. After one hour at room temperature, N-
propargyl maleimide (0.17 mg, 1.25 µmol) diluted in DMSO (100 µl) was added and 
stirred for one hour. 200 µl of this solution was dropped slowly under stirring to 
AzMMMan-HSA (1 mg, 0.015 mol, diluted in 1.8 ml PBS buffer, pH 8.0). The click 
reaction was started by addition of click reaction C (30 µl). Click solution C was 
freshly prepared as described in section 3.5. After 4 hours at 20° C, non-conjugated 
PEG polymer and dye were removed by centrifugation steps with Amicon Ultra 
centrifugal filter units (MWCO 10,000) (×2 washing steps with PBS buffer pH 7.3), 
yielding the TMR-PEG-HSA conjugate. The release kinetic experiment with this 
conjugate was performed as described above in section 4.6.2 (release of alkyne dye 
from conjugate). Absorption was measured at a wavelength of 543 nm. 
 
Material and Methods  55 
4.6.6 Acid catalyzed release of nlsEGFP from 386-DB CO -
AzMMMan-nlsEGFP 
4.6.6.1 Qualitative release 
Samples of 386-DBCO-AzMMMan-nlsEGFP (compound 9, Scheme 5.8) were 
acidified to pH 5 by dialysis against citric acid-phosphate buffer (0.1 M, pH 5) at 37° 
C overnight. The dialysis was performed using a 14000 MWCO dialysis membrane 
from Carl Roth (Karlsruhe, Germany). After that time the protein solution was 
neutralized using Tris buffer (1 M, pH 9.0). Afterwards protein samples (about 20 µg) 
were loaded on a SDS-PAGE gel (12.5%) and run at 160 V for 2 hours. After 
electrophoresis the gel was stained with comassie solution (45/45/10 
water/methanol/acetic acid, v/v/v, and 0.5% w/v comassie brilliant blue G250). Then 
the gel was washed several times with an aqueous solution of acetic acid (7.5% v/v) 
and ethanol (20% v/v). 
 
4.6.6.2 Release kinetics 
To determine the full release kinetic of 386-AzMMMan-nlsEGFP conjugates 
(compound 9, Scheme 5.8) the oligomer 386 was labeled with one equivalent 
tetramethylrhodamine-5-maleimide (TMRM) before coupling. Briefly: 386 (20 mg, 
3.244 µmol) was dissolved in DMSO (400 µl) and TMRM (1.56 mg, 3.244 µmol), 
dissolved in DMSO (400 µl) was added. After one hour at room temperature, 
dibenzylcyclooctyne-PEG4-maleimide (4.38 mg, 6.48 µmol) diluted in DMSO (200 µl) 
was added and stirred for one hour. This was dropped slowly under stirring to 
AzMMMan-nlsEGFP (conjugate 5, Scheme 5.8) (10 mg diluted in 10 ml 0.5 M Hepps 
buffer, pH 8.5). After 4 hours at 20° C non-conjugated polymer was removed by 
centrifugation steps with Amicon Ultra centrifugal filter units (MWCO 10,000) (×2 
washing steps with PBS buffer, pH 7.3). The release kinetic experiment (see Figure 
5) was performed as described above for the release of alkyne dye from conjugate 7 
(Scheme 5.8). Absorption was measured at a wavelength of 543 nm. 
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4.7 Biological characterization of the synthesized 
conjugates 
4.7.1 General procedures 
4.7.1.1 Cell culture 
The used cell lines are listed in Table 3.1. All cultured cells were grown at 37° C in 
5% CO2 humidified atmosphere. HeLa and Neuro2A cells were grown in DMEM (1 g/l 
glucose) supplemented with10% FCS and 100 U/ml penicillin and streptomycin (100 
µg/ml). 3T3 murine fibroblasts cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM), supplemented with FCS (10%), glucose (4 g/l), stable glutamine (4 
mM), sodium pyruvate (1 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL). 
KB cells were cultured in RPMI media without folic acid.  
 
4.7.1.2 Flow cytometry (FACS) 
3T3, HeLa or Neuro2A cells were seeded in 6-well plates (250000 cells/well). After 
transfection and washing as described in the transfection section 4.7.2, cells were 
detached with trypsin/EDTA, diluted with growth media containing 10% FCS, 
harvested by centrifugation and taken up in phosphate-buffered saline with 10% 
FCS. Flow cytometry was performed using a Cyan ADP flow cytometer (Dako, 
Hamburg, Germany). The cellular fluorescence was assayed by excitation of 
nlsEGFP or C12-FDG at 488 nm and detection of emission at 510 nm. To 
discriminate between viable and dead cells as well as for exclusion of doublets, cells 
were appropriately gated by forward/sideward scatter, pulse width and 
counterstained with propidium iodide. 10000 gated cells per sample were collected. 
Data was recorded with SummitT software (Summit, Jamesville, NY). Evaluation was 
done using FlowJo software (Treestar, Ashland, Oregon, USA). 
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4.7.1.3 Fluorescence microscopy and phase contrast microscopy  
For fluorescence microscopy observation, the nuclei of the cells were stained by 
pipetting Hoechst Dye 33342 (1 µg/ml) into the cell culture media. 10 minutes later 
the cells were watched on an Axiovert 200 fluorescence microscope from Zeiss 
(Jena, Germany). A 40x phase 1 objective or a 63x magnification DIC oil immersion 
objective (Plan-APOCHROMAT) and appropriate filter sets for analysis of EGFP and 
Hoechst fluorescence were used. Data were analyzed and processed by AxioVision 
LE software (Zeiss, Jena, Germany). For phase contrast microscopy, also an 
Axiovert 200 microscope from Zeiss (Jena, Germany) was used. Pictures were taken 
using a 10x magnification phase 1 contrast objective. 
 
4.7.1.4 Microinjections 
Microinjections of nlsEGFP, HIV-TATnlsEGFP or carrier modified nlsEGFP were 
performed with a Femtojet microinjector and an Injectman NI2 micromanipulator 
(Eppendorf). HeLa cells were plated onto sterile glass bottom culture dishes. On the 
day of transfection cells have reached a fluency of 70%. A spinning disk confocal 
microscope (BFI Optilas, Dietzenbach, Germany) was used for microinjection. 
Proteins were injected with a concentration of 0.5 mg/ml in PBS buffer.  
 
4.7.2 Protein transductions 
Protein transductions were done similar for all transfections independent of used cell 
line, or used transduction oligomer. Just the used protein concentrations were 
different. 
 
4.7.2.1 Transduction of nlsEGFP 
For fluorescence microscopy, 24 h prior to transfection 20000 cells (HeLa, KB, 
Neuro2A, 3T3) were seeded in 8 well Nunc chamber slides (Thermo Scientific, 
Braunschweig, Germany). Before transfection, medium was replaced with fresh 
medium. Subsequently the oligomer modified nlsEGFP was pipetted into cell culture 
media (10% FCS). After two hours incubation time the cells were washed with PBS 
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buffer (pH 7.3), containing 500 IU heparin per ml. Afterwards fresh medium was 
added and 2 hours later the cells were examined under the microscope. 
For FACS experiments, 24 h prior to transfection 250000 cells were seeded in 6 well 
plates. Before transfection, medium was replaced with fresh medium containing 10% 
FCS. Subsequently the oligomer modified nlsEGFP was pipetted into the cell culture 
media. After incubation (usually 120 min, except for the uptake vs. time experiment 
15; 30; 60; 120; 180 min) cells were washed two times with PBS buffer (pH 7.3; 500 
IU heparin/ ml). 
 
4.7.2.2 Transduction of ß-galactosidase 
Transfection was done quite similar as described above for nlsEGFP. Neuro2A or 
HeLa cells were seeded in 6 well plates (250000 cells per well; one day before 
transduction) and transfected with different concentrations 386-ß-galactosidase for 
two hours.  
For X-Gal staining, a method which was previously described was used (147). After 
transduction, cells were washed with PBS (containing 500 IU heparin per ml and 
subsequently fixed with glutaraldehyde (1.25% (v/v)). Following two additional 
washing steps with PBS, X-gal staining solution (50 mM Tris/HCl, pH 7.5; 5 mM 
potassium ferrocyanate, 5 mM potassium ferricyanate, 15 mM sodium chloride, 1 mM 
magnesium chloride, 0.1% Triton and 0.5 mg/mL X-gal) was added and incubated for 
three hours (37° C). Afterwards the cells were washed once more with PBS and 
analyzed with a phase contrast microscope. 
For quantitative FACS analysis C12-FDG (Invitrogen, Karlsruhe, Germany) substrate 
was used. 250000 Neuro 2A or HeLa cells were seeded in 6 well plates the day 
before transfection. Transduction was done by pipetting 386-ß-galactosidase into the 
growth media. After two hours incubation the cells were washed two times with PBS 
buffer, supplemented with 500 IU heparin per ml. Afterwards the cells were covered 
with fresh growth media containing 2.0 µM C12-FDG. After incubation for 45 minutes, 
the cells were washed again with PBS and evaluated by flow cytometry. 
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4.7.3 Endocytosis inhibition 
This experiment was performed as described elsewhere (148), with minor 
modifications. Briefly: 250000 cells were seeded in 6 well plates. Before transfection, 
medium was replaced with fresh medium containing 1 mM amiloride (inhibitor for 
macropinocytosis), 5 µg/mL chlorpromazine (inhibitor for clathrin-mediated 
endocytosis), or 2.5 mM β-cyclodextrin (inhibitor for caveolae-mediated endocytosis).  
After 30 minutes incubation, the oligomer modified nlsEGFP was pipetted into the cell 
culture media (0.5 µM). Another 120 min later, cells were washed two times with PBS 
buffer (pH 7.3, 500 IU heparin per ml) and subsequently analyzed via flow cytometry 
or fluorescence microscopy. 
 
4.7.4 Cell viability assay 
The metabolic activity of transfected cells was determined by MTT assay. Neuro2A, 
HeLa or 3T3 cells were seeded in 96-well tissue culture plates (TPP, Transdingen, 
Switzerland) at a density of 15000 cells per well, the day before transfection. Cells 
were transfected with different concentrations of 386-nlsEGFP in 100 µL growth 
media (containing 10% FCS) for two hours. After washing with PBS and incubation in 
fresh media (3 h), MTT solution (10 µL per well, 5.0 mg/mL MTT in phosphate-
buffered saline buffer, pH 7.4) was added. The medium was replaced by 100 µL of 
DMSO after 3 h. The optical absorbance was measured at 590 nm, with a reference 
wavelength of 630 nm, by a microplate reader (Spectraflour Plus, Tecan Austria 
GmbH, Austria). The metabolic activity of the transduced cells was expressed as 
relative cell viability, compared to untreated cells. Relative cell viability was defined 
as 
%[ℎ	

] =
590()
590()
100 
 
4.7.5 Activity test of modified ß-galactosidase 
The formation of a fluorescent product (4-methylumbelliferone (4-MU); λexcitation  360 
nm,  λemission 440 nm) out from the nonfluorescent 4-methylumbelliferone-ß-D-
galactopyranoside substrat (MUG) by hydrolysis through ß-galactosidase (149) was 
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used to determine the relative activity of modified ß-galactosidase, compared to 
unmodified enzyme. The assay was performed with minor modification as described 
elsewhere (150). Briefly: MUG (1 mM, non-limiting surplus) substrate was dissolved 
in PBS buffer (pH 7.4; 5 mM MgCl2). The reaction was started by the addition of 
enzyme (0.5 µg/ml). Enzyme kinetic was monitored, by following the formation of the 
fluorescent 4-MU product over time, on a Varian Cary Eclipse fluorescence 
spectrophotometer. As the substrate was used in non-limiting surplus, the enzyme 
activity is displayed by the slope of the curve.  
 
4.7.6 Erythrocyte leakage assay 
This experiment was done quite similar as described elsewhere (62). From fresh, 
citrate-treated blood mouse erythrocytes were isolated and washed in phosphate 
buffered saline (PBS) by four centrifugation steps (800 g, 10 min, 4° C). With PBS 
(pH 7.3) the erythrocytes were diluted to the final cell concentration (5.0x107 
cells/ml). AzMMMAn modified melittin was diluted in PBS buffer (pH 7.3) to give 
melittin concentrations of 5, 2.5, 1.0, 0.5, 0.25 µM. For comparison the same 
concentrations of pure melittin were prepared. The same solutions were prepared 
with PBS buffer (pH 5.0). The acidic samples were preincubated for 3 h at 37° C 
under constant shaking. Meanwhile erythrocyte suspension (75 µL, 3.75x106 cells, 
per well) was pipetted in a V-bottomed 96-well plate (NUNC, Denmark). After mixing 
with 75 µL of the different samples and incubation for 60 min at 37°C under constant 
shaking, the cells were pelletized (800 g, 10 min). The hemoglobin release was 
analyzed by measuring the absorbance of supernatant (80 µl) at 405 nm using a 96-
well microplate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). To 
get data for 100% lysis, erythrocyte suspension (75 µL) was freeze-thawed three 
times and centrifuged (800 g, 10 min) and diluted with PBS buffer (75 µL, pH 7.3). 
Relative haemolysis was defined as: 
 
%[ℎ	

] =
405() − 405()
405( − ℎ) − 405()
100 
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5 Results 
5.1 nlsEGFP as a model protein 
First aim of this work was to establish a cellular test system that enables evaluation 
of the efficiency of the developed protein transduction technologies. For these 
studies nlsEGFP (Figure 5.1) was used as one of two model proteins. 
 
Figure 5.1: 3D structure of EGFP. Calculated with ModWeb and visualized by DeepView version 
4.04. Lysine residues are marked yellow. 
For multiple reasons nlsEGFP presents a good model for intracellular protein 
transduction. Most important its fluorescent properties can be used to pursuit its 
cellular uptake, qualitatively with a fluorescent microscope, or in a more quantitative 
fashion with FACS experiments. Furthermore with a molecular weight of around 31 
kDa, it represents a protein of average molecule size. With an isoelectric point 
around 6.5 it is only slightly charged at physiological pH value of 7.4. An additional 
feature is, that its fluorescence intensity is pH dependent (Figure 5.2). At pH 5.0 that 
is found in late endosomes the absorbance is only about 10 percent of the 
absorbance at pH 7.5. This finding is consistent with the pH dependent fluorescence 
reported for EGFP (151). High cellular fluorescence is a hint for successful 
endosomal escape of the transduced nlsEGFP, because protein encapsulated in 
acidic late endosomes shows only marginal fluorescence. The nuclear localization 
signal (derived from SV40 large T-antigen) fused to the N-terminus is a second 
property that is indicating endosomal escape as free cytosolic protein should be 
translocated into the nucleus (152).   
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Figure 5.2: Fluorescence of nlsEGFP at different pH  values. Fluorescence is normalized to the 
mean value at pH 7.5. 
 
 
5.1.1 Cloning, heterolog expression and purificatio n of nlsEGFP 
and TAT-nlsEGFP 
The gene encoding for nlsEGFP was amplified from the vector pc1068-pRHGPCNA 
and provided with new cloning sites for the insertion into the expression vector pET 
23a(+) by PCR reaction. The successful amplification is shown in Figure 5.3. 
 
Figure 5.3: PCR amplification of nlsEGFP gene from plasmid pc1068-pRHGPCNA (Scheme 9.1). 
Lane 1: DNA standard; Lane 2: PCR product. 
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After cloning and transformation into E. coli expression strain BL21DE3, protein 
expression was induced. Figure 5.4 and Figure 5.5  are documenting the purification 
of the HIS tagged nlsEGFP and the HIV-TAT bearing counterpart over affinity 
chromatography. Both proteins were obtained in over 90 percent purity.  
 
Figure 5.4: Purification of nlsEGFP over affinity c hromatography. Lane1: Protein Ladder; Lane2: 
E.coli lysate; Lane 3: flow through; Lane4-6: wash steps; Lane 7-9: elution fractions. 
 
Figure 5.5: Purification of nlsEGFP over affinity c hromatography. Lane1: Protein Ladder; Lane2: 
E.coli lysate; Lane 3-6: wash steps; Lane 7-9: elution fractions. 
From a four liter overnight E. coli culture in TB medium about 50 mg of pure protein 
were obtained. The fluorescence properties of both proteins were evaluated by 
measuring absorbance and fluorescence spectra (Figure 5.6). Both proteins exhibited 
a fluorescence maximum at about 510 nm. Absorption maxima were detected at 
around 400 nm and 490 nm for both proteins. The extinction coefficient was around 
55000 at pH 7.4. All these data is consistent with values found for EGFP in literature.  
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Figure 5.6: Fluorescence and absorption spectra of nlsEGFP and nlsEGFP-TAT. Blue lines 
present extinction spectra; green lines present emission spectra. 
 
5.1.2 Microinjection of nlsEGFP and TAT-nlsEGFP 
As already mentioned above the nuclear localization signal was fused by genetic 
engineering to the model protein to indicate successful endosomal escape of the 
transduction shuttles. To evaluate the functionality of the fused nuclear localization 
signal (derived from SV 40 large T-antigen) nlsEGFP was microinjected into the 
cytosol of HeLa cells. The fluorescence microscope pictures in Figure 5.7 show that 
injected nlsEGFP is translocated into the nucleus very fast. Already 30 minutes after 
microinjection quite a large amount of the protein was transported into the nucleus. 
The second picture reveals that the amount of subcellular translocated nlsEGFP is 
further increased after 120 minutes. From this point of time further incubation did not 
enhance the amount of protein that is transported into the nucleus (Figure 5.7, 
picture C).    
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Figure 5.7: Microinjection of SV40nls-EGFP in HELA cells. A) 30 min after microinjection; B) 120 
min after injection; C) 180 min after injection. 
The nuclear translocation was also investigated for the PTD tagged nlsEGFP. Figure 
5.8 exhibits that TAT-nlsEGFP is also transported into the nucleus. The nuclear 
transport is even faster than the translocation observed for the counterpart without 
the CPP. Already 15 minutes after injection almost all injected TAT-nlsEGFP is found 
in the nucleus. Beside faster transport into the nucleus also the percentage of cellular 
protein translocated into the nucleus is higher. In contrast to nlsEGFP without fused 
CPP the protein is not distributed homogeniously in the nucleus, but rather 
concentrates in the nucleoli. This finding is consistent with literature that describes 
the same finding for other HIV-TAT tagged proteins (153, 154).     
 
Figure 5.8: Microinjection of TAT-nlsEGFP in HELA c ells . A)  bright-field picture was taken 
immediately before microinjection; B) EGFP fluorescence 15 min after injection. 
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5.2 Protein transduction with TAT-nlsEGFP 
The establishing of a standard protein transduction technology with the model protein 
nlsEGFP was one aim of this thesis. The standard technology should enable the 
possibility to directly compare the efficiency of new developed protein transduction 
techniques. For this reason as already mentioned an nlsEGFP protein that is carrying 
the HIV-TAT protein transduction domain was created. The HIV-TAT cell penetrating 
peptide is built up from mostly cationic amino acids that effect first binding of the 
protein to the negative charged cell surface followed by cellular internalization. As the 
HIV-TAT peptide is one of the mostly used CPPs for protein delivery it should serve 
as a “gold standard” when comparing other techniques with this standard method. 
Figure 5.9 shows pictures taken on a fluorescence microscope of cells transfected 
with a concentration of 2.5 µM TAT-nlsEGFP. The bright field Image reveals that this 
treatment is well tolerated by the cells. Strong EGFP fluorescence of the transfected 
cells is observed using this transduction concentration. Furthermore the fluorescence 
picture reveals that the protein is not equally distributed inside the cell which is a first 
hint that quite a great amount of protein is entrapped in endosomes. Another 
indicator for this hypothesis is the fact that only a small amount of protein is found in 
the nucleus.     
 
Figure 5.9: Transduction of 3T3 cells. A) Brightfield picture of transduced cells; B) EGFP 
fluorescence; C) Hoechst 33342 stain of nucleus. 
To obtain more quantitative information of the uptake and internalization efficiency 
FACS measurements of cells transfected with different concentrations of TAT-
nlsEGFP were done. The experiment shown in Figure 5.10 displays that cells treated 
with a transfection concentration of 0.5 µM exhibit stronger fluorescence than 
untreated cells or cells treated with nlsEGFP without fused TAT protein transduction 
domain. At a concentration of 1.5 µM nearly 100 percent of the cells are found to be 
EGFP positive. As expected the fluorescence intensity is increased with raising the 
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transfection concentration from 0.5 to 1.5 µM. Further increase of the concentration 
to 5.0 µM does not boost the fluorescence intensity much. 
 
Figure 5.10: Transduction of 3T3 cells with differe nt concentrations of TATnlsEGFP. 
Although the brightfield picture in Figure 5.9 which shows nicely shaped cells gave a 
first hint that TAT-nlsEGFP is well tolerated by the cells, this theory should be 
confirmed by doing a cell viability assay. The result of such a MTT assay experiment 
is highlighted in Figure 5.11. Up to a concentration of 1 µM cell viability is not more 
affected by treatment with TAT-nlsEGFP compared to nlsEGFP.  At higher 
concentrations the toxicity is slightly higher than the one observed for the counterpart 
without TAT sequence. But even at the highest tested concentration of 5.0 µM 
around 60 percent of the metabolic activity compared to untreated cells is observed. 
 
Figure 5.11: Cell viabiltity of 3T3 cells treated w ith different amounts of nlsEGFP-TAT or 
nlsEGFP.  
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5.3 Cationic lipid mediated protein delivery 
Most commercial available protein transduction carriers are based on cationic lipids. 
Also for comparison reasons this technique was tested for its ability to mediate 
successful transduction of the model protein nlsEGFP. Murine fibroblast cells were 
transfected with 1 µM nlsEGFP complexed with the cationic lipid SAINTphd. Under 
the tested serum containing conditions almost no cellular uptake could be observed 
(Figure 5.12).  
 
Figure 5.12: 3T3 cells transfected with the cationi c lipid SAINTphd. Nucleus was stained with 
Hoechst 33342 after transduction. 
 
5.4 Dendrimer based protein transduction 
5.4.1 Synthesis of G3 PPI-nlsEGFP 
Protein delivery mediated by structure defined polycationic carrier molecules was one 
of the major aims of this thesis. By Russ et al. modified generation 3 
polypropylenimine dendrimers were previously used successfully for gene delivery 
(155). Inspired by these promising results the properties of this carrier molecule for 
protein transduction should be investigated. For most proteins even those who 
possess a low isoelectric point the negative charge density in contrast to nucleic 
acids is not high enough for creating stable complexes mediated just by ionic 
interactions. Therefore it was decided to covalently couple the dendrimers to the 
protein surface. For the establishment of the covalent bond the terminal amines of 
the dendrimer on the one hand and the carboxylic groups of the protein on the other 
hand were used. As illustrated in Scheme 5.1 the carboxy side chain of aspartate 
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and glutamate was activated with the zero length crosslinker EDC, resulting in stable 
amide bonds between the PPI dendrimer and nlsEGFP. 
 
 
Scheme 5.1: Covalent coupling of G3-PPI dendrimer t o nlsEFGP. Because of better clarity only a 
generation 2 dendrimer is shown. 
Successful modification of nlsEGFP with G3 PPI dendrimer was proven by SDS-
PAGE. The SDS gel in Figure 5.13 reveals 3 different bands for the reaction product. 
These bands correspond to nlsEGFP molecules bearing 1 to 3 PPI dendrimers on 
the surface. Without further purification this mixture of different dendrimer-nlsEGFP 
conjugates were used for transfection experiments. 
 
Figure 5.13: Modification of nlsEGFP with G3-PPI de ndrimer. Lane 1: protein ladder; Lane 2: 
unmodified nlsEGFP; Lane 3: G3-PPI modified nlsEGFP . 
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5.4.2 Protein transduction with G3 PPI-nlsEGFP 
Transduction studies with the G3 PPI-nlsEGFP conjugate were done on the murine 
fibroblast cell line 3T3. FACS experiments (Figure 5.14) reveal that G3 PPI is a highly 
effective carrier molecule for protein delivery. Already with a transfection 
concentration of 0.01µM nearly 100 percent of 3T3 cells are EGFP positive. To reach 
the same fluorescence level when doing transfection with PTD bearing nlsEGFP, 
almost 0.5 µM protein have to be used. As expected Figure 5.14 shows that higher 
transfection concentration leads to higher cellular uptake and therefore brighter 
EGFP fluorescence is observed. 
 
Figure 5.14: Transfection of 3T3 cells with G3 PPI- nlsEGFP. Average cellular EGFP 
fluorescence intensity of 3T3 murine fibroblasts af ter transduction with different 
concentrations of G3 PPI-nlsEGFP. 
Aside the necessary transfection concentration, it was evaluated if transfection time 
has got an influence on cellular internalization. The examination of FACS data shown 
in Figure 5.15 reveals a quite linear dependency of cellular fluorescence and 
transfection time for up to three hours when a concentration of 0.1 µM G3 PPI-
nlsEGFP is used. This observation is a hint for endocytosis as uptake mechanism.    
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Figure 5.15: Transfection of 3T3 cells with G3 PPI- nlsEGFP. Average cellular EGFP 
fluorescence intensity of 3T3 murine fibroblasts af ter different transfection times. Transfection 
was done with 0.1 µM G3 PPI-nlsEGFP. 
To get more information about internalization and especially about endosomal 
escape, transfected cells were watched on a convocal fluorescence microscope. 
Figure 5.16 illustrates bright fluourescence of 3T3 cells transfected with 0.5 µg per ml 
G3 PPI-nlsEGFP in the cell medium. The protein seems to be quite equally 
distributed in the cytoplasm which is a first hint for successful endosomal escape. 
Although due to the nuclear localization signal of nlsEGFP, free cytosolic protein 
should be subcellularly translocated into the nucleus, only small amounts of protein 
are found in the nucleus. The nlsEGFP protein seems to stick to negative charged 
cell components like the nuclear membrane and the endoplasmatic reticulum.   
 
 
Figure 5.16: Transfection of 3T3 murine fibroblasts  with G3PPI-nlsEGFP. 
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In addition to high transfection efficacy, an appropriate transduction shuttle system 
should be well tolerated by the cells. To investigate G3 PPI-nlsEGFP under this 
aspect a cell viability assay, whose examination is displayed in Figure 5.17  was 
done. The figure approved the apprehension that emerged during FACS 
measurements and observation of the cells under the microscope. G3 PPI-nlsEGFP 
is very toxic for cells already in low concentrations. Toxicity occurs already when cells 
are treated with only 0.05 µM G3 PPI-nlsEGFP. With a transfection concentration of 
0.5 µM cells exhibit only 50 percent of the metabolic activity compared to untreated 
control cells.  
 
 
 
Figure 5.17: Cell viabiltity of 3T3 cells treated w ith different amounts of nlsEGFP or G3PPI-
nlsEGFP. 
 
5.4.3 Microinjection of G3 PPI-nlsEGFP 
Although the high cellular toxicity, which aggravates the application of covalently 
coupled G3 PPI as a protein transduction system, the second diagnosed drawback of 
this technology, the bad subcellular translocation into the nucleus should be 
investigated further. Figure 5.7 shows that unmodified nlsEGFP is translocated very 
fast into the nucleus after microinjection. In contrast only small amounts of G3 PPI-
nlsEGFP are found in the nucleus of microinjected HeLa cells after 15 minutes 
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(Figure 5.18). 90 minutes after injection the situation is almost the same. The nucleic 
membrane shows bright EGFP fluorescence. The small amount of protein that was 
transported into the nucleus is concentrated in the nucleoli. This observation is a 
well-known phenomenon for highly positive charged proteins. Microinjection 
reinforces the hypothesis that G3 PPI-nlsEGFP is sticking due to its high positive 
surface charge to negative charged cellular components like the nuclear membrane 
and therefore nuclear transport is hampered.  
 
Figure 5.18: Microinjection of G3PPI-nlsEGFP. A) Pi cture was taken 15 minutes after injection. 
B) Picture was taken 90 minutes after injection. 
 
5.5 Protein transduction with G3PPI coupled to nlsE GFP 
over a bioreversible bond 
5.5.1 Synthesis of G3PPI-SS-nlsEGFP 
To overcome the problem of the unnatural subcellular behavior of G3 PPI-nlsEGFP in 
comparison to unmodified nlsEGFP, the dendrimer should be coupled reversible to 
the protein. The bond between carrier and protein should be cleaved after cellular 
uptake resulting in cytosolic nlsEGFP without dendrimer modification. For introducing 
such a cleavable bond the protein as well as the dendrimer was modified with the 
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crosslinker SPDP. The G3PPI was reduced with DTT resulting in a thiol bearing 
dendrimer. This dendrimer could be simply reacted with SPDP modified nlsEGFP. 
 
Figure 5.19: Synthesis of biological reversible G3P PI-SS-nlsEGFP. G3-PPI was modified with 
SPDP and subsequently reduced. nlsEGFP was modified with SPDP crosslinker. 
Figure 5.20 shows the successful modification of the protein with the dendrimer. 
Furthermore it reveals that the binding between carrier and protein is cleaved in 
presence of reducing agents resulting in nlsEGFP without covalent dendrimer 
modification. 
 
 
Figure 5.20: SDS-PAGE showing successful modificati on of nlsEGFP with G3PPI over 
reducible disulfide bond. Lane1: protein ladder; La ne2: native nlsEGFP; Lane 3: G3PPI-SS-
nlsEGFP: Lane 4: reduced nlsEGFP; Lane 5: reduced G 3PPI-SS-nlsEGFP 
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5.5.2 Protein transduction using G3PPI-SS-nlsEGFP 
Again as with the noncleavable counterpart transfection studies were done on 3T3 
murine fibroblasts. The fluorescent pictures in Figure 5.21 show that nuclear import of 
nlsEGFP after internalization is improved by introducing a biological cleaveable bond 
between the carrier and the protein. The brightfield pictures of cells transfected with 
G3 PPI-SS-nlsEGFP (data not shown) are indicating that toxicity is not significant 
reduced in comparison to the stable construct.  
 
 
Figure 5.21: Transfection of 3T3 murine fibroblasts  with G3PPI-nlsEGFP. A) EGFP fluorescence; 
B) Merged LM-micrograph: EGFP fluorescence and Hoechst fluorescence of the nucleus. 
FACS experiments of cells transfected with G3 PPI-SS-nlsEGFP reveal that 
transfection efficiency is not decreased by the implementation of a reducible bond 
between the dendrimer and the nlsEGFP protein. Already a concentration of 0.01 µM 
of G3 PPI-SS-nlsEGFP leads to detectable EGFP fluorescence of the cells (Figure 
5.22). The cellular fluorescence observed for 0.05 and 0.2 µM is also comparable to 
the fluorescence intensity of cells transfected with the same concentration of the non-
cleavable construct (Figure 5.14). 
 
A) B) 
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Figure 5.22: Fluorescence assisted cell sorting of 3T3 murine fibroblasts after transduction 
with varying concentrations of G3PPI-SS-nlsEGFP. I)  Untreated cells; II) Transduction with 0.01 
µM G3PPI-SS-nlsEGFP; III) Transduction with 0.05 µM  G3PPI-SS-nlsEGFP; IV) Transduction 
with 0.2 µM G3PPI-SS-nlsEGFP. 
Cell viability assays confirm the assumption that toxicity could not be reduced by the 
insertion of a cleavable bond between carrier and cargo. Figure 5.23 is showing 
rather even higher cellular toxicity compared to the corresponding values obtained tor 
the non-cleavable construct (Figure 5.17). Already a treatment of cells with 0.1 µM 
reduces the metabolic activity by a third in comparison to untreated control cells. 
 
Figure 5.23: Cell viabiltity of 3T3 cells treated w ith different amounts of nlsEGFP or G3 PPI-SS-
nlsEGFP. 
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5.6 Protein transduction using the structure define d 
oligomer 386 
Above results show that the G3 PPI dendrimer is an effective carrier for protein 
delivery but its inherent cellular toxicity limits its application. For this reason another 
structure defined carrier with high efficiency and low cytotoxicity should be found. The 
3 arm structure 386 was previously developed as a carrier for the delivery of DNA 
and siRNA. In case of nucleic acid delivery it combines high efficiency with low 
cytotoxicity (59, 156). The transduction oligomer 386 is a structure defined cationic 
oligomer which is built up from natural and artificial amino acids. The main 
components are succinoyl tetraethylene pentamine units which are supposed to be 
important for endosomolytic activity and three cysteine residues on the end of each 
arm. These cysteine residues should enable coupling to cargo molecules as well as 
lateral stabilization through the formation of disulfide bonds.   
 
Scheme 5.2: Structure of 386. x=H; Stp, succinoyl tetraethylene pentamine; C, cysteine; K, α,ε-
modified branching lysine. 
 
5.6.1 Synthesis of reducible 386 modified nlsEGFP 
The three cysteine residues on the terminus of the oligomer arms should be used for 
reversible covalent coupling to the nlsEGFP protein. The coupling strategy is 
illustrated in Scheme 5.3. 
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Scheme 5.3: Synthesis of 386-SS-nlsEGFP. Step 1: modification of nlsEGFP with SPDP. Step 2: 
coupling of 386 to SPDP-nlsEGFP. 
 
To enable an effective coupling of the carrier nlsEGFP was modified with the 
commercial available heterobifunctional crosslinker SPDP. After modification with the 
linker under the used conditions (4.4.1.1), nlsEGFP is exposing around five activated 
thiol groups on the surface that enable fast formation of covalent disulfide bonds with 
the transduction oligomer 386. Successful modification of nlsEGFP with the 
transduction oligomer 386 as well as reversibility of the binding in presence of 
reducing agents is evidenced in Figure 5.24. Dynamic light scattering reveals particle 
sizes of 26.8 +/- 3.6 nm and a zeta potential of 12.4 +/- 0.6 mV. 
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Figure 5.24: SDS PAGE documenting successful modifi cation of nlsEGFP with transduction 
oligomer 386 and reversibility of the bond. Lane 1: Protein ladder; Lane 2: Unmodified nlsEGFP; 
Lane 3: 386-SS-nlsEGFP; Lane4: reduced 386-nlsEGFP. 
 
5.6.2 Protein transduction with 386-SS-nlsEGFP 
Protein transduction ability of the 386 oligomer was evaluated on two different cell 
lines. In a first experiment for direct comparison to G3 PPI dendrimer and PTD-
nlsEGFP 3T3 murine fibroblast cells were transfected and efficiency was evaluated 
by FACS studies. Although the transfection efficiency is lower than the one of 
covalently coupled G3 PPI it is far higher in comparison to TAT-nlsEGFP (Figure 
5.25). 
 
Figure 5.25: Fluorescence assisted cell sorting of 3T3 murine fibroblasts after transduction 
with varying concentrations of 386-SS-nlsEGFP. I) U ntreated cells; II) Transdsuction with 
unmodified nlsEGFP 5µM; III) Transduction with 0.5µ M TAT-nlsEGFP; IV) Transduction with 1.5 
µM TAT-nlsEGFP; V) Transduction with 0.25 µM 386-SS -nlsEGFP; VI) Transduction with 0.5 µM 
VII) Transduction with 0.75 µM.; VIII) Transduction  with 1.0 µM. 
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The mean cellular fluorescence intensity of 386-SS-nlsEGFP treated cells is about 
twenty times higher than the mean fluorescence of TAT-nlsEGFP treated ones. 
Controls which were treated with a high concentration (5µM) of unmodified nlsEGFP 
showed only negligible raise in fluorescence. The same experiment was done with 
Neuro2A cells. Transfection efficiency on Neuro2A cells was slightly lower, compared 
to 3T3 cells transfected with the same amount of modified Protein. Fluorescent 
intensity of Neuro2A cells compared to 3T3 cells was around 55 % lower for cells 
transfected with 0.25 µM, at higher concentrations the mean fluorescence intensity 
was around 20 percent lower (Figure 5.26). We had expected that uptake efficiency 
is concentration dependent, this was already reported for CPP assisted transfection 
studies (102). Nevertheless the nearly perfect linear relationship between transfection 
concentration and fluorescence intensity, for both cell types, in the tested 
concentration area was a little bit surprising. Linear dependency of concentration and 
uptake was already reported for internalization mediated by the protein transduction 
domain Antp (Antennapedia-homeodomain) (100). 
 
Figure 5.26: Concentration dependent cellular uptak e of 386-SS-nlsEGFP. Cells were 
transfected with different amounts of 386-SS-nlsEGF P. White bars: 3T3 cells. Grey bars: 
Neuro2A cells. 
In a following experiment we found that uptake of 386-SS-nlsEGFP and therefore 
observed fluorescence intensity is increasing with incubation time (Figure 5.27). After 
an incubation time of 15 min around 45 percent and after 30 min incubation already 
over 90 percent of the cells were EGFP positive, when transfection was done with 0.5 
µM 386-SS-nlsEGFP. Again, like in the concentration dependent uptake experiment 
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we could find approximately a linear relationship between fluorescence intensity and 
time. Such a continuous uptake is supposed to be a strong hint for endocytosis 
mediated uptake (100). 
 
 
Figure 5.27: Time dependency of protein transductio n with 0.5 µM 386-SS-nlsEGFP on 3T3 
cells. I) Untreated cells; II) Cells transfected wi th 386-SS-nlsEGFP for 15 minutes. III) 30 min 
incubation; IV) 60 min incubation; V) 120 min incub ation VI) 180 min incubation. 
To investigate the ability of these transduction shuttles to penetrate cells, promote 
endosomal release and following subcellular transport. Uptake and subcellular 
distribution were also pursued on a fluorescence microscope. Figure 5.28 is 
demonstrating nicely that all cells were transfected successfully after an incubation 
time of two hours, using a 0.5 µM concentration of 386-SS-nlsEGFP. The cells show 
homogenous cytoplasmic fluorescence. This suggests endosomal escape of the 386-
SS-nlsEGFP. Moreover, the protein is concentrated in the nucleus of the cells, which 
gives again a strong hint for successful escape of the transduction shuttles out of the 
endosomes. Cells treated with unmodified nlsEGFP, as a control, do not show any 
fluorescence. 
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Figure 5.28: . Transduction of 3T3 cells with 386-S S-nlsEGFP. TOP: Transduction with 386-SS-
nlsEGFP. Bottom: Transduction with unmodified nlsEGFP. A) bright-field picture of the transfected 
cells, B) EGFP fluorescence of the transfected cells, C) Hoechst 33342 DNA stain of the cell nucleus. 
Transduction oliogomer 386 has been shown to exhibit low cytotoxicity when used as 
a carrier for siRNA or DNA (59, 156). Because of its internal amide bonds it is 
supposed to be degraded intracellularly by proteases. To verify the nontoxic 
properties for siRNA delivery also in case of being covalently bound to a protein, a 
cell viability test was performed that confirmed this assumption. Figure 5.29 shows 
the low toxicity of the transduction shuttle, even at high transduction concentrations. 
It exhibited only marginal higher toxicity than the cells treated with unmodified 
nlsEGFP protein. With the standard concentration used for the transfections above 
(0.5 µM) a decline in metabolic activity of only 10 percent in comparison to untreated 
cells was observed. Even after transfection with 2.5 µM 386-SS-nlsEGFP cell viability 
decreased by only 25%. 
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Figure 5.29: Cell viabiltity of 3T3 cells treated w ith different amounts of nlsEGFP or 386-SS-
nlsEGFP. White bars: cells transfected with unmodified nlsEGFP. Grey bars: cells transfected with 
386-SS-nlsEGFP 
Flow cytometry experiments using 0.5 µM 386-SS-nlsEGFP also demonstrate that 
internalized nlsEGFP is disappearing after a few days (Figure 5.30). This finding was 
expected, as due to cell proliferation the intracellular nlsEGFP concentration is dying 
out and of course the principal reason is proteosomal degradation. 24 hours after 
transfection cells lost approximately one third of their original mean fluorescence. 
Within 48 hours after transfection the fluorescence decreased to a fourth and after 72 
hours to below 10 percent of the primordial value. 
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Figure 5.30: Cellular fluorescence intensity of cel ls after treatment with 386-SS-nlsEGFP at 
different times. 
As already mentioned in the section above the linear relationship of transfection time 
and uptake efficiency gave a first hint for an endocytotic uptake mechanism. To 
confirm this hypothesis, further experiments were done. Transfection at 4°C lowers 
internalization of the modified protein (Figure 5.31) in 3T3 cells dramatically. Cells 
transduced at 4°C exhibited only 25 percent of the fluorescence compared to control 
cells transfected at 37°C. This observation is indicating that internalization of 386 
modified nlsEGFP is an energy dependent process and is consistent with most CPPs 
(102, 148, 157). To further analyze the endocytotic pathway in 3T3 cells, transfection 
experiments in presence of chlorpromazine (inhibits clathrin mediated endocytosis), 
amiloride (inhibits macropinocytosis) and ß-cyclodextrin (inhibits caveolae mediated 
endocytosis) were done. All this endocytosis inhibitors reduce transduction efficiency 
at least a little bit, suggesting that all three endocytosis pathways participate in 
internalization. Clathrin mediated endocytosis is the predominantly internalization 
route, as chlorpromazine reduces cellular fluorescence to 55 percent compared to 
control cells, transduced under standard conditions. Caveolae mediated endocytosis 
and macropinocytosis seem to contribute respectively to around 15-20 percent of the 
uptake. The finding that clathrin mediated endocytosis may be the major 
internalization route is in accordance with the measured particle size, as particles 
smaller than 200 nm are supposed to be taken up mainly through this pathway (158). 
Aoyama and coworkers found that receptor-mediated endocytosis is strongly size-
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dependent with an optimum of around 25 nm (159-161). That correlates exactly with 
the measured size of the transduction shuttles and the observed uptake pathway. 
 
Figure 5.31: Average cellular fluorescence intensit y of 3T3 cells after transduction with 386-
nlsEGFP at 4°C and in presence of three different e ndocytosis inhibitors: Amiloride, 
chlorpromazine and ß-cyclodextrin. Fluoresence intensity is normalized to cells transduced at 37 °C. 
 
5.6.3 Transduction of 386-SS-ßgalactosidase 
Aside the development of a carrier system for protein delivery, one of the major aims 
of this thesis is the establishing of a test system for protein delivery. nlsEGFP is a 
good model to observe uptake and internalization, but a potential therapeutic 
applicable protein transduction system has to demonstrate that enzyme activity is 
maintained during the delivery process inside the target cell. For this reasons ß-
galactosidase from E.coli was modified with the cationic transduction oligomer 386, to 
demonstrate on the one hand the ability of the carrier to transduce also big molecules 
(464-kDa homo-tetramer), but in the first instance this model should show that 
enzyme activity is maintained inside the target cell. 
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5.6.3.1 Synthesis of 386-SS-ßgalactosidase 
Coupling was done again over the SPDP linker (as described under the material and 
methods part), resulting in a biological reversible bond of the transduction oligomer to 
ß-galactosidase. Each ß-gal molecule was modified with an average of 8 linker 
molecules. Through covalent coupling of the transduction oligomer 386 to linker 
modified ß-galactosidase, particles of 48.3 +/- 2.4 nm with a surface charge of 9.5 +/- 
0.2 mV arise.  
 
5.6.3.2 Activity of modified ß-galactosidase 
To determine the relative activity of modified ß-galactosidase, compared to 
unmodified enzyme, the formation of a fluorescent product (4-methylumbelliferone (4-
MU); λexcitation  360 nm,  λemission 440 nm) out from the nonfluorescent 4-
methylumbelliferone-ß-D-galactopyranoside substrat (MUG) by hydrolysis through ß-
galactosidase (149) was quantified. Figure 5.32 displays that ß-galactosidase is 
losing nearly 85 percent of its enzyme activity during the modification process. 
 
 
Figure 5.32: Enzyme activity of 386-SS-ßGal in comp arison to unmodified ß-galactosidase. Dots 
activity of unmodified ß-galactosidase. Squares activity of 386-SS-ßgalactosidase.  
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5.6.3.3 Transfection experiments with ß-galactosida se 
Although enzyme activity is hampered by the modification, transfection experiments 
with the carrier modified enzyme were done. 386-SS-ßgal was transduced into 
Neuro2A cells, as described under materials and methods. First a qualitative 
experiment should show if any enzyme activity at all could be verified, or if activity 
was lost completely during modification, transfection, internalization or possible 
intracellular degradation. Transduced ß-gal is able to hydrolyse X-Gal (5-bromo-4-
chloro-3-indoxyl-β-D-galactopyranosid) substrate into ß-galactose and its colored 
product 5-bromo-4-chloro-3-hydroxyindole (162) (Figure 5.33). Only cells that were 
transduced with 386-SS-ßgal are blue tinted. Control cells which were treated with 
unmodified ß-gal, before incubation with X-Gal substrate, do not show any staining. 
Therefore we can conclude that transduction of ß-galactosidase was successful and 
a certain enzyme activity is maintained. 
 
Figure 5.33: Transduction of Neuro2A cell with ß-ga lactosidase. Comparison of Neuro2A cells 
after treatment with 386-ß-galactosidase (right) washing and following incubation with X-Gal (5-bromo-
4-chloro-indolyl-β-D-galactopyranoside) substrate. Left: Transduction with unmodified, natural ß-
galactosidase. 
For a more quantitative analysis we used C12-FDG substrate, which led to FITC 
fluorescence after cleavage. Fluorescence was quantified by flow cytometry. We 
observed considerable fluorescence of the 386-SS-ßgal transduced cells but not for 
cells transduced with unmodified ß-gal (Figure 5.34). Therefore we could conclude 
that transduction oligomer 386 is able to transport remarkable amounts of active ß-
gal enzyme into cells, even at the low transduction concentration of 1µM. 
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Figure 5.34: Fluorescence assisted cell sorting of Neuro2A cells following transduction with 
different concentrations of 386-SS-ßgalactosidase w ashing and incubation with C12-FDG 
substrate. I) control, untreated cells; II) Cells transfected with 2.5 µM unmodified ß-galactosidase; III) 
Cells transducted with 1.0 µM 386-SS-ßgalactosidase; IV) Cells treated with 2.5 µM 386-SS-
ßgalactosidase. 
 
5.7 Development of acid labile, traceless heterobif unctional 
click linkers for protein delivery 
The third main aim of this thesis was the development of a linker for protein delivery. 
This linker should allow easy and highly effective covalent coupling of the carrier 
molecule to the cargo protein without many side reactions. It was desired that the 
whole surface of the protein could be modified and therefore the cargo protein could 
be completely encaged by the transduction oligomer. Furthermore the linker should 
enable cleavage between the internalized protein and the transduction carrier under 
mild biological conditions. The cleavage should be triggered by the tiny chemical 
changes, occurring during internalization and further intracellular processing. Last but 
not least it would be in favor, if the linker is cleaved off traceless and therefore 
releases the cargo in its natural unmodified state.  
 
5.7.1 Synthesis of MAM linker 
Blättler and Coworkers (134) presented in 1985 a linker based on maleic anhydride. 
It is the only linker described in literature so far, which may fulfill (except of 
bioorthogonality) all of the desired requirements. The linker was synthesized as 
described by Blättler et al. and illustrated in Scheme 5.4 with acceptable yield.  
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Scheme 5.4: Synthesis of MAM linker. 
 
5.7.2 Acid lability of MAM linker 
The MAM linker was evaluated, if it is applicable for protein delivery. Therefore 
nlsEGFP was modified with the MAM linker and subsequently the transduction 
oligomer 71 (Scheme 5.5) was covalently coupled. Transduction oligomer 71 was 
designed and synthesized by Christina Troiber (AK Wagner, LMU) as part of her phd 
work. 
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Scheme 5.5: Structure of polymer 71.  Drawn by Christina Troiber (AK Wagner, LMU) 
 Figure 5.35 is showing the result of such a modification procedure. The band in lane 
3 reveals that modification was successful. Due to the hydrophobicity of the carrier 
the modified protein is running deeper into the SDS-PAGE, although it is of higher 
molecular weight than the unmodified protein (lane 2). Lane 4 and 5 were charged 
with modified protein after acidic incubation. The modification seems to be partly 
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reversible but only at very low pH values. Because of the insufficient release and the 
low required pH for cleavage, the linker is not really useful for protein delivery.  
 
Figure 5.35: Modification of nlsEGFP with MAM linke r and transduction oligomer 71. Lane 1: 
Protein ladder; Lane 2: unmodified nlsEGFP; Lane 3: nlsEGFP-MAM-71 pH 8.5; Lane 4: nlsEGFP-
MAM-71 after incubation at pH 5.0; Lane 5: nlsEGFP-MAM-71 after incubation at pH 3; 
Although the experiment above showed insufficient release of the carrier from the 
protein under biological relevant conditions, transduction experiments with polymer 
71 coupled via the MAM linker to nlsEGFP were done. 
The pictures taken on the fluorescent microscope and shown in Figure 5.36 reveal 
that polymer 71 is able to deliver covalently bound nlsEGFP into 3T3 cells. But the 
pictures also indicate that quite a great amount of the protein seems to be 
encapsulated in endosomes and therefore only small amounts of nlsEGFP are 
translocated into the nucleus of the cells.  
 
Figure 5.36: Transduction of 3T3 cells with 71-MAM- nlsEGFP. A) bright-field picture of the 
transfected cells, B) EGFP fluorescence of the transfected cells, C) Hoechst 33342 DNA stain of the 
cell nucleus. 
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5.7.3 Synthesis of AzMMMan linker 
As already mentioned so far no linker, which fulfills all requirements for protein 
delivery was described in literature so far. In recent years click chemistry reactions, 
especially the copper catalyzed 1,3-dipolar cycloaddition (CuAAC) and the 
Staudinger ligation, became useful tools for conjugating biomolecules (49, 135-137). 
Both reactions have great advantages compared to other linking strategies, like high 
efficiency and bioorthogonality. Nevertheless, as already mentioned above, for the 
application in protein delivery, a completely bioreversible bond would be favorable. 
Dimethylmaleic anhydride is known to form amide bonds with amines that are 
cleaved under very mild acidic conditions (62, 125, 163-166). The new linker based 
on substituted dimethylmaleic anhydride should combine the advantages of click 
chemistry with the implementation of a pH sensitive bond between conjugated 
biomolecules. This linker should  be labile under mild acidic conditions, which are 
typical for early endosomes (133). Moreover this linker should be cleaved off 
traceless, resulting in an unmodified molecule of interest. Scheme 5.6 is showing the 
structure and the synthesis strategy for the new AzMMMan linker. The azidomethyl-
methylmaleic anhydride linker (compound 3, Scheme 5.6) (AzMMMan) was 
synthesized from dimethylmaleic anhydride by two simple reaction steps (radical 
substitution with N-bromosuccinimide resulting in bromomethyl methylmaleic 
anhydride (compound 2, Scheme 5.6), followed by a type of Finkelstein reaction with 
sodium azide). The overall synthesis yield is 49 percent. 
 
Scheme 5.6: Synthesis of AzMMMan linker. a) N-bromosuccinimide, benzoyl peroxide, 56% b) 
sodium azide, 88%. 
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5.7.4 Synthesis of water soluble alkyne hemicyanine  dye 
The water soluble alkyne dye was used on the one hand to determine the degree of 
protein modification with the new linker and on the other hand to investigate cleavage 
kinetics under acidic conditions. Scheme 5.7 is illustrating the synthesis strategy for 
the new alkyne dye. In the first step methylbenzothiazole was reacted with 
propargylbromide. The reaction yield is 21 percent of the theoretical value. In the 
following condensation reaction the reaction product was transformed with 4-N,N-
bishydroxyethyl aminobenzaldehyde (78 % yield).  
 
Scheme 5.7: Synthesis of hemicyanine dye. a) propar gyl bromide, acetonitrile, 21%; b) 4-N,N-
bishydroxyethyl aminobenzaldehyde, ethanol, 78%. 
 
 
Figure 5.37: Absorption spectrum of alkyne hemicyan ine dye.  
After purification the characteristics of the dye were investigated. It is well soluble in 
water and has got an absorption maximum at a wavelength of 530 nm. For this 
reason it is easy to determine dye coupled to HSA, as HSA does exhibit nearly no 
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absorption at this wavelength. The molar extinction coefficient is 35000 M-1cm-1 in 
PBS buffer (pH 8.5). 
 
5.7.5 Modification of proteins with AzMMMan 
The heterobifunctional linker was used to introduce acid labile azido groups into 
human serum albumin (HSA), EGFP, or ß-galactosidase (ß-Gal) (Scheme 5.8 step a) 
by reaction of the maleic anhydride moiety with amino groups of the proteins. In 
subsequent reactions (Scheme 5.8 step b-e) the linker modified proteins were 
reacted with dye (to determine the amount of coupled linker, acid lability) or 
transduction oligomer for protein delivery investigations. 
 
Scheme 5.8: pH-reversible modification of proteins with AzMMMan and following click 
mocifications with dyes, PEG, or transduction oligo mer. a) Modification of nlsEGFP, HSA, or ß-
Gal with AzMMMan linker 3. CuAAC conjugation of AzMMMan-HSA 4 with b) alkyne-hemicyanin dye 
12 or  d) alkyne-PEG, resulting in conjugates 7 or 8, respectively. c) Staudinger ligation of Dylight 488 
(R4) to AzMMMan-HSA resulting in conjugate 11. e) Conjugation of AzMMMan-nlsEGFP 5 or 
AzMMMan-ß-Gal 6 with carrier polymer 386 (R1) via copper free cycloaddition resulting in conjugate 9 
or 10, respectively. 
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5.7.5.1 Determination of AzMMMan modification degre e of HSA 
HSA was reacted with different linker concentrations. After purification of the reaction 
batches, the reaction products were reacted with a surplus of alkyne dye. The degree 
of linker modification could be determined by measuring the absorbance of the 
coupled dye in conjugate 7 (Scheme 5.8). As expected, the number of azides 
introduced in HSA was nearly linear to the initial concentration of AzMMMan (Figure 
5.38). 
 
Figure 5.38: Reaction of HSA with different concent rations of AzMMMan . The number of azido 
groups incorporated into HAS was determined by reaction of compound 4 (Scheme 5.8 ) with alkyne 
dye.  
 
5.7.5.2 Acid lability and serum stability of AzMMMa n-HSA-Alkyne dye 
Figure 5.39 displays the kinetics of pH-dependent cleavage of dye-conjugate 7 
(Scheme 5.8). Dye labeled HSA 7 (Scheme 5.8) was incubated in buffers of different 
pH. The cleavage of alkyne dye from the protein was determined at various times by 
measuring residual dye absorbance of purified protein fractions.  At basic pH of 8.5 
the conjugate was quite stable, with only about 25 percent cleavage after 24 hours. 
In contrast, at pH 6 the same amount was released already after 30 minutes. Half-life 
at pH 5 is about half an hour, whereas at pH 4 already 90 percent of the linker was 
cleaved in that time. The cleavage of the linker appears to follow a pseudo first order 
kinetic. 
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Figure 5.39: Acid catalyzed release of alkyne dye f rom conjugate 4 (Scheme 5.8) at 37° C. 
Samples of 4 (Scheme 5.8) were incubated in buffers of different pH. At each time point, the fraction 
(%) of dye remaining conjugated with HSA was determined after protein purification. Percentage of 
released dye is calculated as (100- % HSA conjugated dye). 
Figure 5.40 reveals that conjugate 7 (Scheme 5.8) is quite stable under physiological 
serum conditions at 37 °C. After 2 hours incubation in buffer containing 30% FCS still 
94 % of the dye remained coupled to HSA. Even after an incubation time of 12 hours 
60 % of the bonds still are intact. The cleavage rate does not differ much from 
incubation in pure PBS buffer at physiological pH (Figure 5.39). 
 
Figure 5.40: Serum stability of conjugate 7 (Scheme  5.8) at 37° C. Samples of 7 were incubated 
in PBS buffer pH 7.4 containing 30 % FCS. Dye remai ning conjugated with the protein was 
determined by measuring the absorbance of the conju gate after purification from released dye. 
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Aside the copper catalyzed cycloaddition reaction shown in the section above also 
the so called Staudinger ligation can be performed with the azido-proteins (Scheme 
5.9) (137).  
 
Scheme 5.9: Staudinger Ligation . Reaction mechanism of phosphines with azides. 
 
A phosphine containing dye was coupled to AzMMMan-HSA 4 (Scheme 5.8, step c), 
resulting in conjugate 11 (Scheme 5.8). Figure 5.41 shows similar pH-dependent 
cleavage of the two HSA conjugates independent of dye was coupled by Staudinger 
ligation (compound 11, Scheme 5.8) or by CuAAC (compound 7, Scheme 5.8). 
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Figure 5.41: Comparative release of dye coupled ove r Staudinger Ligation and CuAAc. White 
bars: HSA-dye conjugate 7 (Scheme 5.8), generated with alkyne dye via CuAAC. Patterned bars: HSA 
dye conjugate 11 (Scheme 5.8), generated with phosphine dye via Staudinger ligation. 
 
5.7.5.3 Modification of melittin with AzMMMan 
Modification of melittin, the active lytic peptide from bee venom (26 amino acids) 
demonstrates, what great influence blocking of amino groups can have on 
functionality of molecules. Figure 5.42 illustrates, that melittin is losing its lytic activity 
towards erythrocytes when the amino groups are reacted with the AzMMMan 
crosslinker. The lytic activity is retrieved back under mild acidic conditions. This 
experiment shows that for some applications it might be necessary that not only the 
binding between crosslinked molecules is divided, but rather the linker molecule itself 
is cleaved off traceless to release the molecule of interest in its natural unmodified 
condition. 
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Figure 5.42: Acid lability of melittin modification . Hämoglobin release assay from erythrocytes 
incubated with unmodified melittin at pH 7.3 and 5.0 in comparison to AzMMMAn modified melittin at 
pH 7.3 and pH 5. 
 
5.7.5.4 Click modification of AzMMMan-HSA with PEG 
Another application of the AzMMMan linker is reversible PEGylation of proteins 
(Scheme 5.8, step d). Figure 5.43 gives evidence that HSA can be effectively 
coupled with alkyne bearing PEG (lane 3). The PEG conjugate 8 (Scheme 5.8) 
shows extended stability at physiological pH (lane 4) but is cleaved under very mild 
acidic conditions of pH 6 (lane 5). At pH 5 or 4 almost all PEG is released (lanes 6 
and 7). 
 
Figure 5.43: Acid catalyzed release of PEG from HSA  conjugate 8. SDS-polyacrylamide gel 
electrophoresis after 16 h incubation. Lane 1 marke r, lane 2 unmodified HSA, lane 3 pH 8.5, 
lane 4 pH 7.3, lane 5 pH 6, lane 6 pH 5, lane 7 pH 4. 
A more detailed cleavage kinetic of PEG-AzMMMan-HSA at the endosomal pH of 5 
is displayed in Figure 5.44. For this purpose PEG was distally end-labeled with 
tetramethylrhodamine (TMR) dye. The release of TMR-PEG from HSA conjugate was 
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determined at various times by measuring absorbance of TMR dye remaining 
incorporated in purified PEGylated protein conjugate. In contrast to the type of 
coupling reaction which has a minor influence on cleavage kinetics (Figure 5.41) the 
coupled molecule has more impact on acidic bond cleavage. PEG release from the 
protein was considerably slower compared with dye release from conjugate 7 
(Scheme 5.8) (Figure 5.39). 
 
Figure 5.44: Kinetics of PEG release from HSA conju gate at endosomal relevant pH of 5 and 
stability of the conjugate at physiological pH of 7 .3. TMR-labeled PEG released from HSA protein 
was determined by comparing the absorbance of the intact PEG-HSA conjugate before and after 
incubation. 
 
5.7.5.5 Protein transduction using acid labile AzMM Man click linker and 386 
Protein transduction, i.e. the intracellular delivery of proteins, can take advantage of 
the endosomal acidification process (108, 167, 168). nlsEGFP bearing a nuclear 
localization sequence (which mediates natural active nuclear import once a protein 
resides in the cytosol) was bound to the three-arm cationic oligo(aminoethane) amide 
386 (Scheme 5.8, step e) resulting in conjugate 9. Cationic carriers like 386 
containing diaminoethane motifs bind cells and act as proton sponges which upon 
endosomal acidification become increasingly positively charged, triggering endosome 
disruption and release of its content (110, 169). For intracellular delivery of nlsEGFP 
protein, two different linking strategies, conventional irreversible conjugation and pH-
reversible conjugation, were compared. For the synthesis of an irreversible 
conjugate, the commercial linker SMCC was used, resulting in thioether linkage. In 
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the new strategy, oligomer 386 was coupled with AzMMMan-nlsEGFP by copper-free 
cycloaddition via dibencylcyclooctyne (Scheme 5.8, step e). Thus conjugate 9 
contains an acid-labile bond between carrier 386 and nlsEGFP, which is expected to 
be reversible in the endosomal microenvironment before transfer into the cytosol. 
Successful modification of the nlsEGFP protein with transduction oligomer 386 and 
acidic lability of the resulting conjugate 9 (Scheme 5.8) is shown in Figure 5.45. 
 
Figure 5.45: SDS-PAGE gel is showing the successful  modification of nlsEGFP with oligomer 
386 and acid lability of the AzMMMan construct. Lane 1: protein standard ladder; lane 2: 
unmodified nlsEGFP; lane 3: conjugate 9 (nlsEGFP conjugate with 386 via AzMMMan linkage); lane 4: 
nlsEGFP conjugate with 386 via irreversible SMCC modification; lane 5: conjugate 9 (Scheme 5.8) 
after acidic incubation at pH 5; lane 6: nlsEGFP-386 conjugate via SMCC modification, after acidic 
incubation at pH 5. 
The cleavage kinetics was determined in more detail (Figure 5.46) by labeling the 
386 carrier with TMR dye and further processing analogously as described for the 
investigation of PEG release from HSA (Figure 5.44). As already observed for the 
PEG-HSA conjugate, coupling of carrier 386 to nlsEGFP is retarding the cleavage 
kinetics. Nevertheless, after 1 hour incubation at endosomal pH 5.0, >20% and after 
2 hours almost 50% of the transduction oligomer was released from the nlsEGFP 
protein.  
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Figure 5.46: Acid catalyzed release of TMR-386 from  conjugate 9 (Scheme 5.8) at 37° C. 
Samples of TMR-labeled 9 were incubated in PBS buff ers of pH 7.3 and pH 5.0. Dye labeled 386 
released from the protein was determined indirectly  by measuring the absorbance of the 
conjugate after purification. 
The cell culture experiment shown in Figure 5.47 demonstrates how important 
intracellular cleavage can be for protein delivery in the case of covalent binding to a 
carrier molecule using the novel AzMMMan linker. Both constructs, based on the pH-
reversible conjugation or on conventional irreversible conjugation by SMCC thioether 
linkage, were able to deliver nlsEGFP into the cytosol of HeLa cells (Figure 5.47, row 
1 and row 2). Flow cytometry experiments suggest that the stable thioether construct 
seems to be slightly more efficient (data not shown). Cells in row 3 were transfected 
with unmodified nlsEGFP as a control. The fluorescence image shows that no protein 
was internalized. However, only nlsEGFP which had been coupled to the carrier by 
acid labile bonds was further translocated into the nucleus to a large extent (Figure 
5.47, row 1). Transfection of cells with conjugate 9 (Scheme 5.8) at 4° C in the 
presence of three different endocytosis inhibitors (amiloride (inhibitor for 
macropinocytosis), chloroproamzine (inhibitor for clathrin-mediated endocytosis), β-
cyclodextrin (inhibitor for caveolae-mediated endocytosis)) almost completely 
eliminates internalization (Figure 5.47, row 4). This observation suggests an active, 
energy dependent internalization mechanism. The experiment shown in Figure 5.47, 
row 5 evidences that acidification in the endosome is a critical requirement for 
intracellular release of the carrier. Cells were preincubated and transfected in the 
presence of chloroquine and ammonium chloride. Both substances prevent 
acidification of the cellular endosomes. Transfections under these conditions result in 
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a similar observation that was made for the noncleavable construct. The conjugate is 
taken up by the cell and the balanced distribution suggests at least some endosomal 
escape, but only minor translocation of the protein into the nucleus was observed.  
 
Figure 5.47: Transduction of HeLa cells with 386 mo dified nlsEGFP. Row 1: carrier 386 was 
coupled with nlsEGFP via the cleavable AzMMMan linker (compound 9, Scheme 5.8). Row 2: carrier 
386 was coupled by irreversible SMCC thioether linkage. Row 3: transfection was done with 
unmodified nlsEGFP. Row 4: transfection with conjugate 9 (Scheme 5.8 ) at 4°C in presence of 
endocytosis inhibitors. Row 5: transfection with conjugate 9 in presence of endosome acidification 
inhibitors.  A) Brightfield picture of the transfected cells, B) EGFP fluorescence of the transfected cells, 
C) Hoechst 33342 DNA stain of the cell nucleus. 
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Transduction oligomer 386 has been shown to exhibit low cytotoxicity when used as 
a carrier for siRNA or DNA (59, 156). To verify the nontoxic properties also in case of 
being covalently bound to a protein over an acid labile bond, a cell viability test was 
performed that confirms this assumption. Figure 5.48 shows the low toxicity of the 
transduction shuttle, even at high transduction concentrations. It exhibits only 
marginal higher toxicity than the unmodified nlsEGFP protein. With the standard 
concentration used for the transfections above (10 µg/ml) a decline in metabolic 
activity of only 10 percent in comparison to untreated cells is observed. Even after 
transfection with the highest tested concentration of 80 µg/ml 386 nlsEGFP conjugate 
cell viability decreased by only 33%. The toxicity profile of stable and reversible 
bound carrier does not differ much. However at the highest tested concentration the 
irreversible SMCC construct seems to be slightly more toxic. 
 
 
Figure 5.48: Cell viability assay of HeLa cells tra nsfected with different concentrations of 386-
nlsEGFP conjugates. Unmodified nlsEGFP was used for comparison. 
To investigate if the protein conformation is irreversible changed through the 
modification with the AzMMMan linker and the transduction oligomer 386 a CD 
spectroscopy experiment was performed. We compared unmodified nlsEGFP with 
with AzMMMan linker and 386 modified nlsEGFP after acidic incubation and 
purification. Figure 5.49 shows that the cd spectra of unmodified nlsEGFP and 
conjugate 9 (Scheme 5.8) after acidic incubation and purification do not differ much. 
This indicates that the natural conformation of the nlsEGFP protein is not disturbed 
by the reversible modification. 
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Figure 5.49: CD spectra of unmodified nlsEGFP and o f conjugate 9 (386-AzMMMan-nlsEGFP, 
Scheme 5.8) after acidic incubation and purificatio n. 
Fluorescence properties and also CD spectra of construct 9 (Scheme 5.8) are 
indicating that the protein conformation is not significantly affected by the modification 
with the linker and the transduction oligomer. Therefore we examined whether the 
activity of an enzyme would be maintained and survive the modification, delivery, and 
intracellular release steps. As a model enzyme we have chosen ß-galactosidase (ß-
Gal). It is of rather big size (119 kDa), and the activity of the enzyme in the cytosol 
can easily be investigated by the use of the fluorescent substrates. Carrier 386 was 
covalently bound to the ß-Gal protein over the AzMMMan linker (Scheme 5.8, step 
e), resulting in conjugate 10 (Scheme 5.8). This construct was able to transport 
biological active ß-galactosidase into the cytosol of HeLa cells. ß-Gal activity was 
detected by using the fluorescent substrate C12-FDG (C12-fluorescein-di-beta-D-
galactopyranoside), which exhibits FITC fluorescence after cleavage. This 
fluorescence was determined by flow cytometric analysis. Already with a transfection 
concentration of 1 µM a significant raise in fluorescence was observed. Transfection 
with 2.5 µM ß-Gal further raised fluorescent properties. In contrast, cells treated with 
2.5 µM unmodified ß-Gal (without shuttle) did not show a significant shift in 
fluorescence. This experiment evidences that the transduction shuttle is able to 
transduce biological active proteins into the cytosol of cells. 
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Figure 5.50: HeLa cells were transfected with conju gate 10 (386-AzMMMan-ßGal), washed and 
incubated with C12-FDG substrate and evaluated by f low cytometry. I: untreated cells. II: cells 
transfected with 2.5 µM unmodified ß-Gal. III: cells transfected with 1 µM conjugate 10. IV: cells 
treated with 2.5 µM of conjugate 10. 
 
5.7.5.6 Polycation free protein transduction using a folic acid-PEG conjugate 
and melittin peptide 
As already shown in Figure 5.32 modification of enzymes with the polycation 386 can 
have an influence on enzymatic activity. For this reasons a new polycation free 
transduction shuttle was designed (Scheme 4.2). 
 
Scheme 4.2: Synthesis of a polycation-free protein transduction shuttle. 
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 A folic acid- PEG conjugate (synthesized by Christian Dohmen, AK Wagner as part 
of his phd work) that was recently developed for the delivery of siRNA (49, 63) should 
effect internalization. To enable endosomal escape, additionally the endosomolytic 
peptide mellitin was covalently bound to folic acid-PEG modified nlsEGFP. 
Successful transfection of KB cells with the polycation free transduction shuttle (at a 
concentration of 25 µg per ml) is demonstrated in Figure 5.51 (transduction 
experiment performed by Daniel Edinger, AK Wagner, LMU). Quite a great amount of 
transduction shuttle is internalized and the even distribution of the protein inside the 
cytosol indicates endosomal escape. In addition, the protein is translocated into the 
nuclei of the cells, confirming successful escape of the transduction shuttles out of 
the endosomes and subsequent active nuclear import facilitated by the NLS 
sequence. 
 
Figure 5.51: Transfection of KB cells with FAPEGxMe l-nlsEGFP. A) bright-field picture of the 
transfected cells, B) EGFP fluorescence of the transfected cells, C) Hoechst 33342 DNA stain of the 
cell nucleus. This transduction experiment was performed by Daniel Edinger (AK Wagner, LMU). 
 
5.7.6 Synthesis of PentyneMMan crosslinker 
For some applications it may be of advantage to modify the protein instead of the 
azide with the alkyne. Therefor the alkyne bearing counterpart to the AzMMMan 
linker was synthesized. The pentyne-methylmaleic anhydride linker (PentyneMMan) 
was synthesized from dimethylmaleic anhydride by two simple reaction steps (radical 
substitution with NBS resulting in bromomethyl methylmaleic anhydride, followed by a 
carbon-carbon coupling step (Grignard reaction with 4-bromo-1-butyne). The yield for 
the second reaction step was 31 percent. 
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Scheme 5.10: Synthesis of PentyneMMan linker.  a) N-bromosuccinimide, benzoyl peroxide, 56% b) 
diethyl ether, 31%. 
 
5.7.7 Acid lability of PentyneMMan linker 
To investigate if the PentyneMMan linker shows the same acidic reversibility than the 
AzMMMan linker, HSA was modified with the linker and subsequently an azide 
containing dye was coupled. Dye labeled HSA was incubated in buffers of different 
pH. The cleavage of azide dye from the protein was determined at various times by 
measuring residual dye absorbance of purified protein fractions (Figure 5.52).  At 
basic pH of 8.5 the conjugate was quite stable, with only about 30 percent cleavage 
after 24 hours. At pH 6 nearly 40 % was released already after 30 minutes. Half-life 
at pH 5 is about a quarter hour. At pH 4 over 90 percent of the linker was cleaved in 
30 minutes. The cleavage of the PentyneMMan linker as well as for the AzMMMan 
linker follows a pseudo first order kinetic. In summary the bond formed by the 
PentyneMMan linker seems to be a little bit more acid labile the than the bond formed 
by the AzMMMan linker. 
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Figure 5.52: Acid catalyzed release of azide dye co upled over PentyneMMan to HSA at 37° C. 
Samples of azide dye modified PentyneMMan-HSA were incubated in buffers of different pH. At each 
time point, the fraction (%) of dye remaining conjugated with HSA was determined after protein 
purification. Percentage of released dye is calculated as (100%-HSA conjugated dye). 
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6 Discussion 
6.1 Establishing of a cellular test system for prot ein 
delivery 
Protein delivery into the cytosol of living target cells is a very complex process. Many 
different hurdles have to be overcome on the way into the cytoplasm. The delivery 
process may be subdivided into 5 main uptake steps. First the transduction shuttle 
must stay stable at physiological conditions in presence of serum. The second point 
is effective binding of the carrier system to the surface of the target cell. This binding 
may be mediated either by electrostatic interaction or via specific target cell 
interactions. Once bound to the surface the protein complex has to be internalized by 
the cell. The most common uptake pathway in protein delivery is endocytosis. 
Endocytosis leads to an entrapment of the internalized particle in cellular 
compartments surrounded by a phospholipid bilayer membrane, called endosomes. 
In most cases this endosomes are maturing to acidic lysosomes, leading to 
degradation of the internalized protein by proteases. For this reasons the escape out 
of this endosomal compartment is indispensable for successful protein delivery into 
the cytosol of cells. But even after the carrier-cargo complex has reached the cytosol 
the delivery process is not finished. Now ideally in the fifth and last delivery step, the 
carrier has to be cleaved off from the cargo to assure natural behavior of the 
internalized protein. During all these critical five delivery steps the natural 
conformation of the protein has to be maintained to warrant activity of an internalized 
enzyme for example. A perfect test system for protein delivery should highlight every 
single step of this internalization process isolated. This should enable appropriate 
adjustment of the carrier system in case of one of these critical hurdles is not 
overcome by the transduction shuttle. Moreover a perfect test system should allow 
easy and fast qualitative determination of cellular uptake and further processing. To 
enable the comparison of different protein delivery techniques with regard to 
efficiency the test system should allow aside qualitative uptake the quantitative 
determination of the internalized protein amount and the percentage of successfully 
transfected cells. Of course it will never be completely avoidable that the carrier 
system has to be a little bit adjusted and modified according to the special demand of 
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a certain cargo. Nevertheless the test system should provide a platform that is 
transferable to as much other proteins as possible. Therefor the test proteins should 
be of average protein size and surface charge. Last but not least the test proteins 
have to be available in great quantities. So they have to be either cheaply 
commercially available or have to be easy to express and purify. The protein delivery 
test system developed in this thesis is addressing all requirements mentioned above. 
The nlsEGFP protein is easily heterologously expressable in E. coli and ß-
galactosidase is cheaply commercially available.  As the test proteins nlsEGFP and 
ß-galactosidase are of average protein size and charge, their transfection results 
should be transferable to a great amount of other proteins. Cellular binding and 
uptake, because of the inherent fluorescent properties of nlsEGFP, can be easily 
determined as well qualitative on a fluorescent microscope as well as quantitative via 
FACS analysis. Endosomal escape is indicated by even distribution of the nlsEGFP 
protein inside the cytosol of the transfected cell and more exactly by successful 
subcellular transport. This subcellular transport of nlsEGFP into the nucleus, 
mediated by the tagged nuclear localization signal, is only possible after endosomal 
release. Moreover the results in Figure 5.47 reveal that cleavage between carrier and 
cargo is advertised by the test system. The ß-galactosidase enzyme was used as a 
second test protein which should evidence that the conformation of the proteins is not 
irreversibly disturbed by modification and the subsequent delivery processes. ß-
galactosidase allows also qualitative (Figure 5.33) and quantitative (Figure 5.34) 
conclusion of the transfection efficiency by the use of fluorescence substrates. In 
literature as well nlsEGFP (170) as also ß-galactosidase (147) were already used as 
test proteins for protein delivery. However, only the combination of results obtained 
by transfection experiments with these two test proteins, gives a good hint for a broad 
applicability of the investigated transduction technology.    
   
6.2 Development of a sequence defined carrier syste m for 
protein delivery 
Protein transduction into living cells holds enormous potential in biological as well as 
in medical applications. With few exceptions native proteins, because of their size 
and charge, are unable to penetrate into the cytosol of living cells. Hence, an all-
Discussion  111 
purpose intracellular protein delivery technology is highly desirable as it would open 
the door for reams of different therapeutic uses. As already mentioned in the section 
above, the requirements on such a carrier platform are enormous. The carrier has to 
protect the protein cargo from proteolysis and aggregation in the extracellular space 
of the target cell. Afterwards the carrier has to promote cellular binding and further 
uptake of the complex by the target cell. Once inside the cell the retrograde transport 
out of the endosome mediated by the carrier system is indispensable for successful 
protein delivery. Moreover the carrier system has to combine high transduction 
efficiency with low cytotoxicity. Up to date many different carriers have been 
investigated in regard to exhibit these required properties. Cationic polymers as 
polyethylenimines belong to one of the most effective drug carrier classes and have 
been widely used as well for nucleic acid (126) as for protein delivery (107). 
Polyethylenimine lacks of defined structure and more important exhibits due to the 
big molecule size quite high cellular toxicity (171). For this reasons a generation three 
polypropylenimine dendrimer as carrier was used as a first protein transduction 
carrier molecule. G3 PPI is of rather low molecular weight and furthermore a 
structure defined molecule. Covalent coupling of the G3 PPI dendrimer over the zero 
length crosslinker EDC to nlsEGFP leads to high efficient protein transduction into 
living cells (Figure 5.14). Although the fluorescent pictures show good internalization 
and even distribution of the nls-EGFP protein is indicating endosomal escape, only 
small amounts of the internalized protein is translocated into the nucleus of the 
transfected cells. Also microinjection experiments reveal that G3 PPI modified 
nlsEGFP (Figure 5.18) in contrast to unmodified nlsEGFP (Figure 5.7) is subcellularly 
not transported into the nucleus. The lacking nuclear import of G3 PPI modified 
nlsEGFP is consistent with a direct (by chemical modification of the nls residues) or 
indirect (by sterical shielding) inactivation of the nuclear localization signal. 
Alternatively, active nuclear transport may be hampered by unspecific cytosolic 
retention of the polycationic transduction shuttle. The microinjection pictures of 
G3PPI-nlsEGFP are indicating that the last point may be one of the major reasons as 
quite a great amount of the protein is sticking to negative charged cell components 
for example the nuclear membrane shows high EGFP fluorescence. To achieve 
aside high efficient internalization natural subcellular behavior a cleavable bond 
between theG3PPI carrier and the nlsEGFP cargo was introduced. Transduction 
studies with this G3PPI-SS-nlsEGFP showed a little bit better nuclear translocation 
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compared to the non-cleavable counterpart (Figure 5.21). The shape of cells 
transfected with the reducible construct indicated high cytotoxicity that was further 
evidenced by a performed cell viability assay (Figure 5.23). High toxicity of G3PPI 
was already observed for the noncleavable G3PPI-nlsEGFP construct but the 
significant higher toxicity of the cleaveable G3PPI-nlsEGFP was not expected in that 
extent. The higher toxicity of the cleavable transduction shuttle may be explained with 
the fact that free cytosolic G3PPI dendrimer can interact more with cellular 
components, for example mRNAs, DNA, membranes etc., than protein bound 
dendrimer which is at least partly shielded by the irreversible covalently bound  
nlsEGFP protein. High toxicity is known to be another possible reason for unnatural 
behavior of internalized proteins. This could explain the rather low nuclear transport 
of nlsEGFP, when it is transduced with G3PPI as a carrier molecule, even in cases 
when the bond between carrier and cargo is biological cleavable. To overcome the 
problem of high toxicity other carrier molecules were tested for their applicability in 
protein delivery. Like G3PPI dendrimer, polymer 71 is a structure defined cationic 
oligomer. In contrast to the G3PPI dendrimer that is based on polypropylenimine 
units, polymer 71 is built up from amino acids and fatty acid subunits. The carrier was 
previously designed in the Wagner laboratory for the transfection of DNA and siRNA. 
In these studies it exhibited high transduction efficiency combined with low 
cytotoxicity. Covalent coupling to the nlsEGFP protein over the MAM linker molecule 
was quite difficult. Only low amounts of polymer can be coupled to the protein, 
because otherwise the modified protein is building non soluble aggregates. The 
formation of these aggregates is consistent with the following explanation. 
Transduction oligomer 71 contains oleic acid residues that should enable membrane 
destabilization and therefore endosomal escape. After covalent coupling to the 
protein these fatty acids change the naturally hydrophilic surface of the nlsEGFP 
protein and makes it more hydrophobic. Now van der Waals forces are leading to the 
observed protein aggregation. The weak nuclear transport of nlsEGFP transduced 
with oligomer 71 can be explained in following manner. Because only a small 
modification degree is possible, the amount of carrier covalently bound to the protein 
is not sufficient to promote endosomal escape (Figure 5.36). Another cause for the 
lack of nuclear translocation may be found in insufficient cleavage of the used MAM 
linker and therefore again interaction of the carrier with cellular components hempers 
nuclear transport. For this reasons 386 another structure defined carrier that showed 
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similar good properties for nucleic acid delivery as transduction oligomer 71 was 
used. In contrast to 71, the structure of 386 does not contain fatty acid residues. This 
fact enables a high modification degree of the nlsEGFP without leading to protein 
aggregation and the formation of insoluble particles. The stp subunits, because of 
their high positive charge density effect good cellular binding of 386 modified 
nlsEGFP to the cell surface and therefore internalization of the conjugate. Moreover 
the membrane destabilizing properties of 386 enable good endosomal escape. If 386 
is coupled over a biological cleavable bond to the protein natural behavior of 
cytosolic nlsEGFP is indicated by fast nuclear translocation of free cytosolic nlsEGFP 
(Figure 5.28). Although 386 is showing lower transfection efficiency than G3PPI 
(Figure 5.26), the fact of the low cytotoxicity makes it much more applicable for 
protein delivery. The linear dependency of concentration and uptake that was found 
for 386 modified nlsEGFP was already reported for internalization mediated by the 
protein transduction domain Antp (Antennapedia homeodomain) (100). Furthermore 
an approximately linear relationship between fluorescence intensity and time was 
found. Such a continuous uptake is supposed to be a strong hint for endocytosis 
mediated uptake (100). This hypothesis was further evidenced by uptake inhibition 
experiments. The uptake inhibition experiments did not allow the identification of a 
certain endocytosis pathway, but rather suggest that different mechanisms are 
involved in the internalization process (Figure 5.31). Although it cannot be excluded 
completely that in some cases the observation of reduced uptake may also be 
explained by the toxicity of the inhibitor which leads to lower cellular metabolism. The 
bright fluorescence of 386-SS-nlsEGFP and 386-AzMMMan-nlsEGFP is indicating 
that the conformation of the nlsEGFP is not affected much by the modification. This 
was further evidenced by CD spectroscopy experiments which reveal a natural 
conformation of nlsEGFP after splitting off the carrier (Figure 5.49). Aside the rather 
low sized nlsEGFP, 386 was able to deliver ß-galactosidase with high molecular 
weight into the cytosol of different cell lines. Moreover the enzyme is found to be 
enzymatically active inside the cytosol of the transduced cells. Although enzyme 
activity was found in transduced cells an experiment investigating the kinetics of 
substrate conversion revealed that 386 modified ß-galactosidase exhibits only 10 
percent of the activity compared to untreated enzyme. This finding may be explained 
by the charge inversion of the protein, as unmodified ß-gal is a protein with a 
negative isoelectric point (theoretical pI 5.8), whereas on the modified protein the 
Discussion  114 
positive charges overbalances the negative ones by far. Another possible reason for 
the loss in activity may be the rather rough chemical conditions during the 
modification process. To resolve this problem another carrier system was tested for 
its protein delivery properties. PEG modified folic acid as a targeting ligand and the 
endosomolytic peptide mellittin were covalently coupled to the nlsEGFP. This 
transduction shuttle is completely free of polycations. Ideally, this protein transduction 
shuttle comprises functionalities for all essential steps during the delivery process: 
shielding of the protein during circulation (to prevent immunogenic side effects as 
well as degradation), a targeting moiety (for receptor specific delivery and uptake by 
the target cells) and finally an endosomolytic moiety (for effective release of the 
payload from the endosomal compartment). First transduction studies show 
promising results for the transfection of nlsEGFP (Figure 5.51). 
 
6.3 Design of a traceless-cleavable linker for prot ein 
delivery 
For protein delivery in contrast to nucleic acid delivery in most cases a covalent bond 
between the carrier and the cargo is necessary. Nucleic acids exhibit a high density 
of negative charges resulting in a strong electrostatic interaction between the 
polycationic carrier and the nucleic acid. The formed polyplexes are very stable even 
under serum containing conditions. Although the polar and charged side chains of 
the amino acids are mostly exposed on the surface of the protein whereas the 
hydrophobic residues assemble in the core the charge density is far lower compared 
to nucleic acids. Moreover the surface of most proteins does not only contain 
negative charged moieties resulting from the glutamic acid or asparagine side chains 
but usually also the positive charged side chains of lysine, histidine and arginine 
amino acids are exposed. For example the used nlsEGFP protein is built up of 281 
amino acids, whereof 36 residues are negative charged (aspartate and glutamate) 
and 33 are positive charged (arginine and lysine). This is resulting in a negative 
charge density of one negative charge per 10511 Da. In comparison an average 
double stranded DNA molecule of the same molecular weight exhibits a charge 
density of one negative charge per 312 Da. Regarding this great difference in the 
charge density it becomes clear why proteins do not form stable complexes with 
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polycations, in contrast to nucleic acids. To overcome this problem, different 
strategies were developed. For example each positive charge occurring from a lysine 
residue can be transformed in two negative charges by modification with citraconic 
anhydride. With this strategy the charge density of cytochrome c could be enhanced 
to one negative charge per 320 Da (75). Another strategy for forming stable 
polyplexes is the exploitation of hexa-histidine tag fused to the cargo protein. A 
carrier that contains a chelat forming nitrile triacetic acid complex is binding strongly 
to this histidine tag (27). The major disadvantage of this system is that no complete 
encapsulation of the cargo protein with the carrier is possible as these hexa-histidine 
tags in most cases are either fused to the amino- or to the carboxy-end of the protein. 
In contrast, the covalent coupling of the carrier to lysine residues of the cargo protein, 
over linker molecules, allows complete encapsulation. Up to date many different 
linker molecules for covalent modification of proteins have been developed. Covalent 
modification of proteins can have great influence on their properties. For example the 
bee venom peptide mellittin can lose its lytic activity after covalent modification 
(Figure 5.42). For this reasons most of them are limited applicable for protein delivery 
as they form stable non-cleavable bonds between the carrier and the cargo (e.g. 
amide bonds, thioether and others). Among the biological cleavable linkers the used 
SPDP crosslinker is one of the most famous. The disulfide bonds between the carrier 
and the cargo protein are cleaved by the reducing conditions endemism in the 
cytosol. For protein delivery also acid labile linkers are applicable, due to the 
acidification process occurring in endosomes after internalization of the transduction 
shuttle. Such acid labile linkers have already been described in literature (172-174). 
Major disadvantage of these linkers is the fact that after cleavage of the acid labile 
bond a small linker fragment is retarded on the cargo molecule. The acid labile 
linkers used and developed in this thesis are based on maleic anhydride which forms 
an acid labile amide bond with amines of the cargo molecule. Under acidic 
conditions, this labile amide bond is cleaved traceless, resulting in an unmodified 
cargo molecule. Blatter and coworkers (134) developed a heterobifunctional MAM 
linker based on maleic anhydride. Figure 5.35 and Figure 5.36 show that its 
applicability for protein delivery is limited due to insufficient cleavage of the acid labile 
bond under physiological relevant pH conditions. It is well known that amide bond 
formed by dimethyl maleic anhydride are due to the Thorpe-Ingold effect much more 
acid labile than those formed with maleic anhydride (62). This is also the explanation 
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why the AzMMMan and PentyneMMan linkers, developed in this thesis, are cleaved 
at higher pH values (Figure 5.39, Figure 5.52). How important the cleavage under 
mild physiological relevant conditions is becomes clear when comparing the results 
of nlsEGFP coupled to the carrier molecule over AzMMMan and MAM. nlsEGFP 
coupled to the carrier with AzMMMan shows natural cytosolic behavior and is 
subcellularly transported into the nucleus, whereas nlsEGFP coupled over the MAM 
linker lacks of this translocation due to insufficient cleavage. The experiment in which 
endosomal acidification is prevented with chloroquine is evidencing that cleavage of 
the carrier is indispensable for natural subcellular behavior of nlsEGFP (Figure 5.47). 
Aside the higher acid lability, the developed AzMMMan and PentyneMMan linkers 
have got a second advantage compared to the MAM linker. In recent years click 
chemistry reactions, especially the copper catalyzed 1,3-dipolar cycloaddition 
(CuAAC) and the Staudinger ligation, became useful tools for conjugating 
biomolecules.(49, 135-137) Both reactions have great advantages compared to other 
linking strategies, like high efficiency and bioorthogonality. In contrast the second 
functional group of the MAM linker is a maleimide. This maleidido group is not 
bioorthogonal, as it can react with thiol groups from cysteine residues as well as with 
amine groups from lysine residues for example. Figure 5.41 reveals that the coupling 
type (Staudinger Ligation or CuAAC) has got only a minor influence on the acid 
lability of the construct, whereas the coupled molecule has more impact on acidic 
bond cleavage. PEG release from the protein (Figure 5.44) was considerably slower 
compared with dye release (Figure 5.39). This may be explained by better sterical 
shielding of the maleimido group by PEG. Although the PentyneMMan linker seems 
to be a little more acid labile than the AzMMMan linker they do not differ much in this 
property. The better solubility of the AzMMMan linker tipped the balance why it was 
preferred for use in the protein delivery experiments. 
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7 Summary 
Intracellular protein delivery is offering numerous possibilities in research and in 
therapy. Aside gene therapy, protein delivery into living cells is one of the most 
promising tools for the treatment of various so far immedicable diseases including 
cancer. To develop a practicable protein delivery platform, a test system which allows 
easy control of successful intracellular delivery is needed. Therefore a test system 
based on two model proteins was established. A nuclear localization signal tagged 
EGFP molecule is enabling fast control of cellular uptake and endosomal release. 
The second model protein ß-galactosidase is evidencing that protein conformation is 
not irreversible disturbed by modification with the carrier molecules. Protein 
transduction technology is opening the door for a promising alternative to gene 
therapy, as it is lacking of the potential malignant side effects of gene therapy. The 
most limiting step in the development of a therapeutic drug remains the delivery 
process. In the last decade, many techniques to deliver proteins into living cells were 
developed. Although great efforts were made, so far no all-purpose technique is 
available that addresses all critical steps, like efficient uptake, endo-lysosomal 
escape, low toxicity, while maintaining enzymatic activity. Each method has got its 
limitation, for example cell type dependence. Among the so far used carriers, the 
most effective ones are cationic polymers like polyethylenimine. These carriers are 
lacking of precise structure and often show high toxicity, dependent on the molecular 
weight of the used polymer. In this thesis the properties of the three arm cationic 
oligomer 386, which was previously designed for siRNA delivery was investigated in 
regard of being applicable as a transduction carrier for protein delivery. This carrier 
molecule, in contrast to other cationic polymers used for protein delivery, is of precise 
structure, of low molecular weight and potentially degradable by proteases. The 
transduction oligomer was covalently bound to the protein by a bioreversible bond. 
Our results reveal that covalent coupling of the structure defined cationic oligomer 
386 to a protein leads to a high efficient, serum insensitive and low toxic alternative to 
established protein transduction technologies. For a general all-purpose delivery 
system covalent coupling of the carrier to the cargo protein is indispensable. Protein 
delivery requires special properties to the linker molecule. Therefore in this work a 
new pH sensitive linker was developed which combines the advantages of click 
reactions with the implementation of a traceless cleavable bond between two 
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conjugated molecules. Three different click chemistries were performed which all are 
compatible with the acid labile properties. A traceless cleavage may be a particularly 
important feature in protein transduction strategies, to maintain full bioactivity of 
enzymes and other proteins. The current example of 386 carrier-mediated cytosolic 
delivery and subsequent nuclear import of released nls-EGFP demonstrates the 
advantage of the traceless linker. To demonstrate that the modification does not 
irreversibly affect structure and biological activity of proteins, 386-AzMMMan-ß-
galactosidase was delivered as a model enzyme. It exhibited cytosolic activity in the 
transduced cells far higher than without shuttle. Aside from these encouraging 
options for protein delivery and modification, the linker might have broader use in the 
design of novel programmed, acid labile and biodegradable drug delivery systems. 
Targeted therapeutics could, after delivery into acidic tumor areas or upon cellular 
uptake into endosomes, be dismantled from their outer shell including targeting 
ligands. Besides drug delivery, the linker may also be of interest for other 
applications, such as reversible labeling of various biological and also chemical 
molecules. The developed linking strategy and the presented concepts for 
transduction shuttles may help to get a step closer in the design of an all-purpose 
protein delivery platform, applicable on bench as on bedside. 
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8 Abbreviations 
µM   Micromolar 
µmol   Micromole 
AA   Amino acid 
ACN   Acetonitrile 
Antp   Antennapedia homeodomain 
ATCC   American type culture collection 
AzMMMan  Azidomethyl methyl maleic anhydride 
B6   Peptide sequence with affinity for the transferrin receptor 
C12-FDG  5-dodecanoylaminofluorescein di-β-D-galactopyranoside 
Calcd   Calculated 
CD   circular dichroism 
CHCL3  Chloroform 
C-NMR  Carbon Nuclear magnetic resonance spectroscopy  
CPP   Cell penetrating peptide 
CuAAc  Copper catalyzed alkyne azide cycloaddition 
CuBr   Copper bromide 
CuI   Copper iodide 
Da   Dalton 
DBCO  Dibenzylcyclooctyne 
DCC   Dicyclocarbodiimide 
DCM   Dichloromethane 
DCU   Dicyclourea 
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DCVC   Dry column vacuum chromatography 
DIC   Differential interference contrast  
DLS   Dynamic light scattering 
DMF   N,N-Dimethylformamide  
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DTT   DL-Dithiothreitol 
e.g.   Exempli gratia, for example 
EDC   N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EDTA   Ethylenediaminetetraacetic acid 
EGF-R  Epidermal growth factor receptor  
EGFP   Enhanced green fluorescent protein 
Et2O   Diethyl ether  
etc.   Et cetera 
EtOH   Ethanol 
FA   Folic acid 
FACS   Fluorescent analyzed cell sorting 
FCC   Flash column chromatography    
FCS   Fetal calve serum  
FDA   Food and Drug Administration   
FITC   Fluorescein isothiocyanate  
G3   Generation three 
GE 11   Peptide binding to the EGF-receptor  
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GFP   Green fluorescent protein 
GTP   Guanosine 5′-triphosphate    
HCl   Hydrochloric acid 
Hepes  N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid)  
Hepps  N-2-Hydroxyethylpiperazin-N'-3-propansulfonsäure  
HIV   Human immunodeficiency virus  
HMPA  Hexamethylphosphoramide  
H-NMR  Proton Nuclear magnetic resonance spectroscopy 
HSA   Human serum albumine  
IR   Infrared 
IU   International Units 
kDa   kilo Dalton 
Mal   Maleimide 
MAM   Maleic anhydride maleimide    
Mel   Melittin 
MetOH  Methanol 
mg   Milligramm 
MHz   Megahertz 
mL   Milliliter 
mM   Millimolar 
mmol   Millimole 
mRNA  Messenger RNA 
MSN   Mesoporous silica nanoparticle 
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MTBE   Methyl tertiary butyl ether 
MTT   1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan  
MUG   4-Methylumbelliferyl β-D-galactopyranoside 
MWCO  Molecular Weight Cut Off 
NBS   N-Bromosuccinimide  
NHS   N-Hydroxysuccinimide  
NLS   Nuclear localization signal 
nlsEGFP  Nuclear localization signal tagged EGFP 
nm   Nanometer 
NTA   Nitrilotriacetic acid  
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PEG   Polyethylene glycol 
PEI   Polyethylenimine 
PentyneMMan Pentyne methyl maleic anhydride 
pH   Potentia Hydrogenii 
PPI   Polypropylenimine 
PTD   Protein transduction domain 
RGD   Peptide sequence (arginine, glycine, aspartic acid)  
RNA   Ribonucleic acid 
RNAi   RNA interference  
SDS   Sodium dodecyl sulfate 
PAGE   Poly Acrylamide Gel Electrophoresis 
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SEC   Size exclusion chromatography 
siRNA   Small interfering RNA 
SMCC  N-Succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate 
SPDP   N-Succinimidyl 3-(2-pyridyldithio)propionate 
ß-Gal   Beta galactosidase 
Stp   Succinoyl-tetraethylenpentamine 
SWNTs  Single walled carbon nanotubes 
TAT   Trans-Activator of Transcription  
TB   Terrefic Broth  
TBTA   Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amin) 
tertButOH  Tertiary butanol 
THF   Tetrahydrofuran 
TLC   Thin layer chromatography 
TMR   Tetramethylrhodamine 
Tris   Tris(hydroxymethyl)aminomethane 
UV   Ultraviolett 
Vis   Visible 
VLPs   Virus like particles 
X-Gal   5-Brom-4-chlor-3-indoxyl-β-D-galactopyranosid  
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9 Appendix 
9.1 Plasmid maps and base sequences 
9.1.1 pc1068-pRHGPCNA  
 
Scheme 9.1: Plasmid pc1068-pRHGPCNA 
Base Sequence: 
GATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTT
CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGGGGTT
CTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGG
GTCGGGATCTGTACGACGATGACGATAAGGATCGATGGGGATCCCCGAAGAAG
AAGCGCAAAGTACTGGTACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCT
GTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGC
CACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGC
TGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC
CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCA
CATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGG
AGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTG
pc1068-pRHGPCNA
4846 bp
BamHI (203)
EcoRI (1398)
HindIII (2144)
ApaLI (3058)
ApaLI (4304)
ClaI (196)
ClaI (1012)
PstI (1131)
Pst I (1711)
Nco I (246)
Nco I (1218)
Nco I (1950)
SV40-nls-EGFP
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AAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTT
CAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCC
ACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCA
AGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAG
CAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCT
GAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTG
TACAAGGGCGAAGGGCAAGGGCAAGGGCAAGGGCCGGGCCGCGGCTACGCG
TATCGATCCATGTTCGAGGCGCGCCTGGTCCAGGGCTCCATCCTCAAGAAGGT
GTTGGAGGCACTCAAGGACCTCATCAACGAGGCCTGCTGGGATATTAGCTCCA
GCGGTGTAAACCTGCAGAGCATGGACTCGTCCCACGTCTCTTTGGTGCAGCTC
ACCCTGCGGTCTGAGGGCTTCGACACCTACCGCTGCGACCGCAACCTGGCCAT
GGGCGTGAACCTCACCAGTATGTCCAAAATACTAAAATGCGCCGGCAATGAAGA
TATCATTACACTAAGGGCCGAAGATAACGCGGATACCTTGGCGCTAGTATTTGA
AGCACCAAACCAGGAGAAAGTTTCAGACTATGAAATGAAGTTGATGGATTTAGAT
GTTGAACAACTTGGAATTCCAGAACAGGAGTACAGCTGTGTAGTAAAGATGCCT
TCTGGTGAATTTGCACGTATATGCCGAGATCTCAGCCATATTGGAGATGCTGTT
GTAATTTCCTGTGCAAAAGACGGAGTGAAATTTTCTGCAAGTGGAGAACTTGGA
AATGGAAACATTAAATTGTCACAGACAAGTAATGTGGATAAAGAGGAGGAAGCT
GTTACCATAGAGATGAATGAACCAGTTCAACTAACTTTTGCACTGAGGTACCTGA
ACTTCTTTACAAAAGCCACTCCACTCTCTTCAACGGTGACACTCAGTATGTCTGC
AGATGTACCCCTTGTTGTAGAGTATAAAATTGCGGATATGGGACACTTAAAATAC
TACTTGGCTCCCAAGATCGAGGATGAAGAAGGATCTTAGTCTAGAGTCGAGATC
CTGAGAACTTCAGGGTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTTCGCTAT
TGTAAAATTCATGTTATATGGAGGGGGCAAAGTTTTCAGGGTGTTGTTTAGAATG
GGAAGATGTCCCTTGTATCACCATGGACCCTCATGATAATTTTGTTTCTTTCACT
TTCTACTCTGTTGACAACCATTGTCTCCTCTTATTTTCTTTTCATTTTCTGTAACTT
TTTCGTTAAACTTTAGCTTGCATTTGTAACGAATTTTTAAATTCACTTTTGTTTATT
TGTCAGATTGTAAGTACTTTCTCTAATCACTTTTTTTTCAATTCGAAGCTTGATCC
GGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGC
AATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGC
TGAAAGGAGGAACTATATCCGGATCTGGCGTAATAGCGAAGAGGCCCGCACCG
ATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGT
AGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTA
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CACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCG
CCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGG
TTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGAT
GGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTG
GAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACC
CTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTG
GTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAA
CGCTTACAATTTAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTG
TTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGAT
AAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGT
CGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAA
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTA
CATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGA
ACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCC
CGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAAT
GACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACA
GTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAAC
TTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAAC
ATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGC
CATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTT
GCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATA
GACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCC
GGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCG
GTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCT
ACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAG
ATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATA
TACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATC
CTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAG
CGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCG
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTT
GCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGC
GCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGC
TGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTT
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ACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCC
AGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATG
AGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGC
GGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCT
GGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTT
GTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCC
TTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGT
TATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCG
CTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGA
AGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAAT
GCAGAAGGCAATCAGGGTATATTATATTGTACTTCAGCACAGTTTTAGAGAAC 
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9.1.2 pET 23a(+) 
 
Scheme 9.2: Plasmid pET-23a(+) 
Base Sequence: 
ATCCGGATATAGTTCCTCCTTTCAGCAAAAAACCCCTCAAGACCCGTTTAGAGG
CCCCAAGGGGTTATGCTAGTTATTGCTCAGCGGTGGCAGCAGCCAACTCAGCTT
CCTTTCGGGCTTTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCG
AGTGCGGCCGCAAGCTTGTCGACGGAGCTCGAATTCGGATCCGCGACCCATTT
GCTGTCCACCAGTCATGCTAGCCATATGTATATCTCCTTCTTAAAGTTAAACAAA
ATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTC
GCGGGATCGAGATCTCGGGCAGCGTTGGGTCCTGGCCACGGGTGCGCATGAT
CGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTGCCTTACTGGTT
AGCAGAATGAATCACCGATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAA
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ACGTCTGCGACCTGAGCAACAACATGAATGGTCTTCGGTTTCCGTGTTTCGTAA
AGTCTGGAAACGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATC
GCAGGATGCTGCTGGCTACCCTGTGGAACACCTACATCTGTATTAACGAAGCGC
TGGCATTGACCCTGAGTGATTTTTCTCTGGTCCCGCCGCATCCATACCGCCAGT
TGTTTACCCTCACAACGTTCCAGTAACCGGGCATGTTCATCATCAGTAACCCGTA
TCGTGAGCATCCTCTCTCGTTTCATCGGTATCATTACCCCCATGAACAGAAATCC
CCCTTACACGGAGGCATCAGTGACCAAACAGGAAAAAACCGCCCTTAACATGGC
CCGCTTTATCAGAAGCCAGACATTAACGCTTCTGGAGAAACTCAACGAGCTGGA
CGCGGATGAACAGGCAGACATCTGTGAATCGCTTCACGACCACGCTGATGAGC
TTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACA
TGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGA
CAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCA
TGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACTATGCGGCATC
AGAGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGA
TGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGAC
TCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC
GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGC
AAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTT
TCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGA
GGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGC
TCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGC
CTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCT
CAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCG
TTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGG
TAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGA
GCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGG
CTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCG
GTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAG
AAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCAC
GTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT
AAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTG
ACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCG
TTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGG
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CTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGG
CTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGT
GGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCT
AGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTGCA
GGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCC
CAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGC
TCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTC
ATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCT
TTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGC
GACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGC
AGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAA
GGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACT
GATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAG
GCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCAT
ACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCG
GATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATT
TCCCCGAAAAGTGCCACCTGAAATTGTAAACGTTAATATTTTGTTAAAATTCGCG
TTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAAT
CCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGG
AACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACC
GTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTG
GGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATT
TAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAA
GCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCG
TAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCCATTCG
CCA 
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9.1.3 pET 23a(+)-SV40nls-EGFP 
 
Scheme 9.3: Plasmid pET-23a(+)-SV40nls-EGFP 
Base Sequence:  
AGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCT
AACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACT
AGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGG
AGGAACTATATCCGGATTGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAG
CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCC
CTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGC
TTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCT
TTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGG
CCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTT
AATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATT
pET-23a(+)-nlsEGFP
4409 bp
AP r
T7-Tag
His-Tag
Primer T7
bla Promotor
Promotor T7
rbs
pBR322 origin
T7 transcription terminator
SV40nls
BamHI (3642)
BmtI (3613)
EcoRI (3648)
HindIII (1)
Nco I (3691)
NdeI (3604)
Nhe I (3609)
XbaI (3564)
Xho I (16)
SV40nls-EGFP
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CTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCT
GATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTCAG
GTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAAT
ACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAAT
ATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTT
TTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTA
AAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTC
AACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATG
AGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGG
CAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTAC
TCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGC
AGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACG
ATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTA
ACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGA
GCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAAC
TGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGC
GGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTAT
TGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCAC
TGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGT
CAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTG
ATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTT
AAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCA
TGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAG
AAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTT
GCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCT
ACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATAC
TGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC
GCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGA
TAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCA
GCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACG
ACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTT
CCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG
GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCT
GTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGG
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GGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGC
CTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTG
GATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAAC
GACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGG
TATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATATGGTGCACTCT
CAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCG
CTACGTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGC
GCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCG
TCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCG
AGGCAGCTGCGGTAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTC
TGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTG
GCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGA
TGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACG
AGAGAGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGA
ACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAA
TCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGG
GTAGCCAGCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCAGGGCGCT
GACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTCATGTT
GTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCG
TATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGT
CCTCAACGACAGGAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGCTGC
CCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACG
GTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGGCTA
GCATGACTGGTGGACAGCAAATGGGTCGCGGATCCGAATTCCCGAAGAAGAAG
CGCAAAGTACTGGTACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTT
CACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCAC
AAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGA
CCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTC
GTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACAT
GAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGC
GCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAG
TTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAA
GGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACA
ACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAAGA
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TCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAG
AACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAG
CACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCC
TGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTTTAC
AAGA 
 
9.1.4 pET 23a(+)-SV40nls-EGFP-HIVTAT 
 
Scheme 9.4: Plasmid pET-23a(+)-SV40nls-EGFP-HIVTAT 
Base Sequence:  
AGCTTGGTTATGGGCGCAAAAAACGCCGTCAGCGCCGTCGGGGCCTCGAGCAC
CACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGA
GTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAA
ACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATTGGCGAA
TGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGC
GCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTC
pET-23a(+)-SV40nls-EGFP-HIVTAT
4439 bp
AP r
His-Tag
T7-Tag
HIV-TAT
Primer T7
Promotor T7
bla Promotor
rbs
pBR322 origin
T7 transcription terminator
SV40nls
BamHI (3672)
EcoRI (3678)
HindIII (1)
NdeI (3634)
Nhe I (3639)
XbaI (3594)
Xho I (46)
nlsEGFP-TAT
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TTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGG
GGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAA
CTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTT
CGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTG
GAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCC
GATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAAT
TTTAACAAAATATTAACGTTTACAATTTCAGGTGGCACTTTTCGGGGAAATGTGC
GCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATG
AGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTA
TTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTT
TTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGT
GCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGT
TTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTG
GCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATA
CACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTA
CGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATA
ACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACC
GCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCG
GAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGC
AATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCC
CGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTG
CGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGA
GCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCC
GTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATA
GACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACC
AAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGA
TCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTT
TTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGA
TCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCA
GCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACT
GGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTA
GGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATC
CTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGA
CTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTT
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CGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTA
CAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACA
GGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCC
AGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACT
TGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACG
CCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACA
TGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGA
GTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTG
AGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTG
CGGTATTTCACACCGCATATATGGTGCACTCTCAGTACAATCTGCTCTGATGCC
GCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTG
CGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCT
CCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTC
AGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTAAAGCTCA
TCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGC
TCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATG
TTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTT
CTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATACG
GGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACT
GGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGC
GCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGA
TGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTT
ACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTT
TGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAAC
CAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATC
ATGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAGATCTCGATCCCGCGAAA
TTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTG
TTTAACTTTAAGAAGGAGATATACATATGGCTAGCATGACTGGTGGACAGCAAAT
GGGTCGCGGATCCGAATTCCCGAAGAAGAAGCGCAAAGTACTGGTACCGGTCG
CCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAG
GGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCAC
CGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGC
GTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAA
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GTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACG
ACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGT
GAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGG
GGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACA
AGCAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCGAGGAC
GGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACG
GCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGC
AAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGC
CGCCGGGATCACTCTCGGCATGGACGAGCTTTACAAGA 
9.2 Amino acid sequences 
9.2.1 SV40nls-EGFP 
MASMTGGQQMGRGSEFPKKKRKVLVPVATMVSKGEELFTGVVPILVELDGDVNGH
KFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQH
DFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILG
HKLEYNYNSHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLL
PDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKKLAAALEHHHHHH 
 
9.2.2 SV40nls-EGFP-HIVTAT 
MASMTGGQQMGRGSEFPKKKRKVLVPVATMVSKGEELFTGVVPILVELDGDVNGH
KFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQH
DFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILG
HKLEYNYNSHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLL
PDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKKLGYGRKKRRQRR
RGLEHHHHHH  
 
9.2.3 ß-galactosidase 
MTMITDSLAVVLQRRDWENPGVTQLNRLAAHPPFASWRNSEEARTDRPSQQLRSL
NGEWRFAWFPAPEAVPESWLECDLPEADTVVVPSNWQMHGYDAPIYTNVTYPITV
NPPFVPTENPTGCYSLTFNVDESWLQEGQTRIIFDGVNSAFHLWCNGRWVGYGQD
SRLPSEFDLSAFLRAGENRLAVMVLRWSDGSYLEDQDMWRMSGIFRDVSLLHKPT
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TQISDFHVATRFNDDFSRAVLEAEVQMCGELRDYLRVTVSLWQGETQVASGTAPF
GGEIIDERGGYADRVTLRLNVENPKLWSAEIPNLYRAVVELHTADGTLIEAEACDVG
FREVRIENGLLLLNGKPLLIRGVNRHEHHPLHGQVMDEQTMVQDILLMKQNNFNAV
RCSHYPNHPLWYTLCDRYGLYVVDEANIETHGMVPMNRLTDDPRWLPAMSERVTR
MVQRDRNHPSVIIWSLGNESGHGANHDALYRWIKSVDPSRPVQYEGGGADTTATD
IICPMYARVDEDQPFPAVPKWSIKKWLSLPGETRPLILCEYAHAMGNSLGGFAKYW
QAFRQYPRLQGGFVWDWVDQSLIKYDENGNPWSAYGGDFGDTPNDRQFCMNGL
VFADRTPHPALTEAKHQQQFFQFRLSGQTIEVTSEYLFRHSDNELLHWMVALDGKP
LASGEVPLDVAPQGKQLIELPELPQPESAGQLWLTVRVVQPNATAWSEAGHISAW
QQWRLAENLSVTLPAASHAIPHLTTSEMDFCIELGNKRWQFNRQSGFLSQMWIGD
KKQLLTPLRDQFTRAPLDNDIGVSEATRIDPNAWVERWKAAGHYQAEAALLQCTAD
TLADAVLITTAHAWQHQGKTLFISRKTYRIDGSGQMAITVDVEVASDTPHPARIGLNC
QLAQVAERVNWLGLGPQENYPDRLTAACFDRWDLPLSDMYTPYVFPSENGLRCG
TRELNYGPHQWRGDFQFNISRYSQQQLMETSHRHLLHAEEGTWLNIDGFHMGIGG
DDSWSPSVSAEFQLSAGRYHYQLVWCQK 
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9.3 Analytic spectra 
9.3.1 Alkyne hemicyanine dye 
 
Figure 9.1:  1H NMR of 2-[2-(4-Dihydroxyethylamino-phenyl)-vinyl] -3-prop-2-ynyl-benzothiazol-3-
ium bromide 12. 
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9.3.2 AzMMMan linker 
 
 
Figure 9.2: 1H NMR of 3-(azidomethyl)-4-methyl-2,5- furandione. 
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Figure 9.3:  13C NMR of 3-(azidomethyl)-4-methyl-2,5-furandione. 
 
 
Figure 9.4: IR spectrum of 3-(azidomethyl)-4-methyl -2,5-furandione. 
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Figure 9.5: DEI + mass spectra of AzMMMan. 
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9.3.3 PentyneMMan linker 
 
Figure 9.6: 13CNMR of PentyneMMan. 
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Figure 9.7: 1HNMR of PentyneMMan 
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Figure 9.8: IR spectra of PentyneMMan. 
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Figure 9.9: DCI + mass spectra of PentyneMMan. 
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